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Abstract 
Introduction: Cerebral small vessel disease (cSVD) is an important, but relatively 
poorly understood cause of both lacunar strokes and vascular dementia.  Structural 
magnetic resonance imaging (MRI) markers of cSVD, including lacunes, white matter 
lesions (WML) and microbleeds, have been shown not to correlate consistently with 
clinical severity, as gauged by cognitive decline, and might offer little more than 
endpoint markers of disease.  However, alternative developing MR techniques, 
including functional MRI (fMRI) using the blood-oxygen-level-dependent (BOLD) 
signal, offer a promising approach to charting disease severity.   
Aims: The primary aim is to determine whether „n‟, a measure of neurovascular 
coupling (NVC) which underpins interpretation of the BOLD signal, differs between 
patients with cSVD and healthy matched controls.  If „n‟ does differ, a secondary aim is 
to determine whether „n‟ correlates with tests of cognitive function. 
Methods: Eleven patients with cSVD and sixteen age-, education- and gender-matched 
healthy controls were recruited.  Participants underwent a battery of cognitive tests 
focused upon executive functions and a series of MRI scans.  These included structural 
scans, arterial spin labelling (ASL) to measure cerebral blood flow and BOLD signal.  
Oxygen calibrated fMRI was used with a modified Stroop Interference Task. 
Results: The cSVD group performed worse on the digit symbol substitution test 
(DSST) (p = 0.00005) than the control group.  There was a significantly different 
BOLD response in 11 regions between patient and control groups, which were 
aggregated into frontal, parietal, motor, insular and total regions.  „n‟ was reduced 
across total regions (p = 0.02) in the patient group.  „M‟ was increased in the patient 
group and correlated inversely with „n‟.  DSST did not correlate with „n‟ in patients.   
Conclusion: The results suggest an uncoupling of the neurovascular response in 
patients with cSVD, possibly associated with an increase in the oxygen extraction 
fraction.  A larger sample size would be needed to investigate whether altered 
neurovascular coupling might highlight at-risk subjects who have not yet had a stroke. 
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Chapter 1: Introduction 
 
1.1 Cerebral small vessel disease 
Cerebral small vessel disease (cSVD) is an increasingly important problem in an ageing 
population (1).  It is responsible for a quarter of all first-ever ischaemic strokes (2-4) 
and is the most common subgroup of vascular dementia (VaD) (5).  cSVD can result in 
a picture of dementia, gait abnormalities, urinary incontinence, dysarthria and mood 
disturbances such as depression and emotional lability (6-8).  The gait is classically 
termed „marche à petit pas’, characterised by small shuffling steps with the arms 
abducted and elbows flexed (6,7).    
 
Patients with cSVD represent a clinically and aetiologically relatively homogeneous 
population (7).  It is a disease of the small perforating end arteries in the brain (5,9).  
cSVD manifests itself as a number of often coexisting conditions, which may be 
additive in their negative effect on the patient‟s long term prognosis (1).  These 
conditions include white matter ischaemic lesions (WML), microbleeds, dilated or 
enlarged perivascular spaces (EPVS), infarcts in a lacunar territory either with a 
concomitant clinical stroke syndrome or clinically „silent‟, plus other silent subcortical 
infarcts (1,10-12).  All of these can be seen on magnetic resonance imaging (MRI) and 
can be considered structural markers of underlying cSVD.  This study primarily aims to 
evaluate the use of a functional MRI (fMRI) marker in patients with cSVD. 
 
1.1.1 White matter lesions 
WML are areas of ischaemic injury of the white matter (13).  Leukoaraiosis (LA), seen 
as hyperintense areas on T2-weighted MRI, is the radiological correlate of the WML 
(9).  Ischaemic leukoaraiosis is a term that assumes cSVD as the likely pathological 
basis of the observed WML, and is usually reserved for radiological LA in a patient 
with a clinical lacunar stroke (9). 
 
WML are caused by cSVD, but are also associated with inflammation, oedema, trauma, 
and toxic and metabolic disorders (13).  WML are also commonly seen in the 
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apparently healthy elderly: the Cardiovascular Health Study (CHS) found that 95.6% of 
3301 community dwelling elderly, aged 65 years or older, without a history of stroke or 
transient ischaemic attack, had evidence of WML (14).  They have been reported in 
64%–100% of patients with VaD and also in 7.5%–100% of those with Alzheimer‟s 
disease, though usually to a less severe extent (15).  
 
The severity of WML in the CHS was 
independently associated with increasing 
age, clinically silent stroke evidenced on 
MRI, raised systolic blood pressure (BP), a 
reduced forced expiratory volume in one 
second, and a lower income (14).  
Longitudinal data from the same study 
found that worsening WML were 
associated with a reduction in the mini-
mental state examination (MMSE) score 
and digit symbol substitution test (DSST) 
score (both measures of cognitive 
function) (16).  The risk factors associated 
with worsening lesions were complexly 
related, but for a low initial severity grade 
worsening WML were associated with 
increased age, diastolic BP and high-density lipoprotein (HDL) cholesterol, and with 
reduced low-density lipoprotein (LDL) cholesterol (16).  The presence of severe WML 
is linked to an increased risk of developing dementia, stroke and disability (17). 
 
Histopathological examination of WML reveals partial loss of myelin sheaths, 
oligodendroglial cells and axons (13).  Pathologically, WML found in the apparently 
healthy elderly, VaD, Alzheimer‟s disease or the damaged tissue between a completed 
infarct and the surrounding normal tissue, are the same (13).  They are thought to be 
caused by hypoperfusion resulting in ischaemic injury of deep white matter (7).   
Figure 1: WML (arrows) on FLAIR (Fluid 
attenuated inversion recovery) image, 
axial view. 
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WML may arise from periodic hypotension in chronically hypertensive patients (18).  
Autoregulation of CBF allows a relatively constant supply of blood within vascular 
beds during variations in arterial pressure (19).   Cerebral resistance arteries dilate in 
response to a reduction in perfusion pressure and constrict in response to an increase in 
pressure (19).  The range of perfusion pressures associated with a constant CBF is 
known as the „autoregulatory plateau‟ (19).  Beyond the perfusion pressure limits of the 
autoregulatory plateau cerebral resistance vessels respond passively (19).  Thus a further 
increase in perfusion pressure beyond the plateau limit would result in increased CBF.  
Chronically elevated BP leads to a rightward shift of the autoregulatory plateau (20).  
This shift is associated with vascular remodelling that results in a reduced external 
vessel diameter and vessel wall hypertrophy, which together lead to a narrower vascular 
lumen (19).  It is believed that chronically hypertensive individuals may be susceptible 
to rapid drops in BP, and may develop ischaemic change in white matter even within the 
BP range considered normal in the non-diseased population (15,21).   
 
Resting CBF has been shown to be reduced in white matter, but not in normal appearing 
grey matter in a study of patients with ischaemic leukoaraiosis (22).  Isaka et al. (23) 
found no reduction in resting CBF in subjects with asymptomatic LA.  However, 
cerebral vasomotor reactivity (VMR; cerebrovascular reserve) was reduced in this 
group.  Marstrand et al. (24) also demonstrated reduced CBF and VMR in WML 
compared with normal appearing white matter.  VMR represents the response of the 
cerebral vessels to a vasodilatory stimulus (25).  VMR has been found to be inversely 
associated with WML (25)(26).  This appears to follow on from the observation of a 
rightward shift of the autoregulatory plateau in chronically hypertensive individuals 
with damage to small cerebral vessels.  In these subjects, cerebral resistance vessels 
would have reduced capacity to further dilate.  Thus with a drop in perfusion pressure or 
administration of a vasodilatory stimulus these vessels would have a more limited 
response than in an asymptomatic normotensive individual. 
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The normal cerebral endothelium is involved in CBF regulation, maintaining the blood-
brain barrier (BBB) and preventing clot formation (27).  In cSVD the endothelium is 
„activated‟ to participate in the inflammatory response (28).  As part of this process 
vascular permeability is increased, resulting in potentially toxic serum proteins entering 
the perivascular neural parenchyma (29).  Chronic endothelial dysfunction has been 
suggested as a cause of WML, resulting from a breakdown of the BBB, impaired 
cerebral autoregulation and/ or prothrombotic changes (27).  Hassan et al. (27) showed 
increased expression of plasma markers associated with endothelial dysfunction in 
patients with cSVD compared to non-stroke controls.  However, a recent systematic 
review does not present convincing evidence that endothelial dysfunction is specific to 
lacunar stroke, having been observed in cortical stroke also (30).   
 
1.1.2 Cerebral microbleeds 
Cerebral microbleeds are seen as 
small hypointense lesions on T2*-
weighted MR images of the brain 
(31).  They correspond to the 
breakdown products of blood, such 
as haemosiderin, that persist in the 
cerebral matter for many years 
following a bleed from damaged 
arterioles (31).  Hypertensive 
lipohyalinotic changes (as seen in 
cSVD; described later) and cerebral 
amyloid angiopathy both lead to 
cerebral microbleeds but with 
differing lesion distributions (32).   
The reported prevalence of 
microbleeds is 11.1%–23.5% in the community-dwelling elderly population (32).  They 
are found in a quarter of patients with ischaemic stroke (31).  Greenberg et al. (32) cite 
evidence to suggest that they might directly damage surrounding tissues leading to 
Figure 2: Susceptibility-weighted image of a 
cerebral microbleed (arrow), axial view. 
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cognitive decline, as well as acting as markers of disease.  A small case-control study 
showed microbleeds to be associated with executive dysfunction in stroke patients, 
independent of WML (31).  Microbleeds are also associated with an increased risk of 
haemorrhagic transformation following ischaemic stroke (31).   
 
1.1.3 Lacunar infarcts 
Lacunar infarcts (LI) are small subcortical 
infarcts that result from occlusion of a 
single penetrating artery of the brain 
(1,2,33).  They tend to occur in the basal 
ganglia, thalamus, internal capsule, corona 
radiata or brainstem (1,33,34).  When the 
infarcts heal, they leave behind a small (3-
15mm) cerebrospinal fluid (CSF)-filled 
cavity, known as a “lacune” (33,35).  
Fisher argues that the term LI ought to be 
reserved only for those lesions believed to 
be of vascular origin (33).  The 
terminology of LI, lacunar strokes and 
lacunes is inconsistently used in the 
literature (35).  In this report the definitions 
set out by Wardlaw (35) shall be used: 
 
 Lacune: CSF-filled cavity.  Radiological infarcts in a lacunar territory shall be 
referred to as lacunes throughout. 
 Lacunar stroke: A clinical stroke syndrome with symptoms suggestive of a small 
subcortical or brainstem infarct. 
 LI: A clinical stroke syndrome with a corresponding lacune (radiological 
infarct). 
 
Figure 3: Lacunar infarct (arrow) on 
FLAIR image, axial view. 
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Lacunes have been classified pathologically into three types by Poirier and Derouesne 
(36), with a further sub-category subsequently added by Lammie et al. (12): 
I. a. Old, small infarct 
b. Old, small “incomplete” infarct 
II. Old, small haemorrhage 
III. Dilated perivascular space 
 
Lacunes cause symptoms if they are located in clinically eloquent sites.  Although small 
lesions, in the region of 3mm to 15mm (however, the definition varies) (1,33), they can 
cause a large deficit if they occur within the long ascending or descending tracts, where 
multiple fibres serving a large proportion of the body are found in close proximity, for 
example a LI might result in weakness of one side of the body (1).  Fisher described 
over 20 varieties of lacunar syndromes (33).  The five best documented are described in 
descending order of frequency in Box 1 (33,37-40). 
 
1.1.4 Silent subcortical infarcts 
Many subcortical infarcts are not evident clinically as a discrete stroke.  They are 
known as „silent‟ infarcts (1).  They are five times more common than LI presenting as 
stroke, being present in over a quarter of all people above seventy years old (1).  Silent 
infarcts are found more often in patients with a LI rather than other ischaemic strokes 
(1).  Although they do not cause a stroke syndrome, silent infarcts are associated with 
cognitive decline, depressive symptoms and a reduced likelihood of functional recovery 
(1,4,41).  Furthermore, their presence doubles the risk of dementia (41).  One theory is 
that „silent‟ lacunar infarcts reduce the capacity for neuroplasticity and recovery 
mechanisms of the brain (1,42).  Any future stroke would therefore lead to reduced 
recovery and so, increased disability.  
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Box 1: Lacunar stroke syndromes in descending order of frequency. 
 
 
 Pure sensory stroke 
o Numbness, with or without severe deficit of other sensory modalities, 
of the face, arm and leg on one side, in the absence of weakness, 
homonymous hemianopia, aphasia, agnosia or apraxia. 
 Although usual, not all three of face, arm and leg need be 
affected. 
o Usual infarct site:  sensory (posteroventral) nucleus of the thalamus 
 Pure motor hemiparesis 
o Pure motor stroke of the face, arm and leg on one side, in the absence 
of sensory deficit, homonymous hemianopia, aphasia, agnosia or 
apraxia 
 All three of face, arm and leg need to be affected. 
o Usual infarct site:  Posterior limb of the internal capsule; lower basis 
pontis where the corticospinal tracts congregate to form the pyramids; 
or, rarely, the mid-portion of cerebral peduncle. 
 Sensorimotor stroke 
o Combination of pure sensory stroke and pure motor hemiparesis. 
o Usual infarct site:  Posterolateral thalamus, extending into the adjacent 
posterior limb of the internal capsule. 
 Ataxic hemiparesis 
o Pure motor hemiparesis with cerebellar dysmetria, not due to 
weakness, in the affected limbs.  Dysarthria, nystagmus and falling to 
one side may be present. 
o Usual infarct site: Pons  
 Dysarthria-clumsy hand syndrome 
o Facial weakness, dysarthria and dysphagia are combined with slight 
weakness and clumsiness of the hand.  No sensory deficit. 
o  Usual infarct site:  Basis pontis 
o Considered a variant of ataxic hemiparesis. 
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1.1.5 Dilated perivascular spaces 
In the central nervous system the CSF-filled cavities between the vessel wall and the 
cerebral parenchyma are known as perivascular, or Virchow-Robin, spaces (PVS) (43).  
These invaginations of subarachnoid space surround arteries, arterioles, veins and 
venules, but not capillaries (43).  PVS allow drainage of the interstitial fluid and also act 
as a channel for inflammatory processes (44).  Pathologically enlarged PVS (EPVS) are 
associated with reduced cognitive function in normal ageing (45), hypertension (44), 
inflammation such as multiple sclerosis (46), lacunar strokes (47) and LA (47).  EPVS 
are also associated with worsening BBB function (48). 
 
EPVS are classified as type III lacunes (12).  On T2-weighted MRI EPVS appear as 
small high-signal areas running in the same direction as penetrating arterioles (47). 
 
1.1.6 Vascular dementia 
Of the population over 65 years, 8% have dementia (18).  VaD is the second commonest 
dementia type, after Alzheimer‟s disease (49,50).  VaD makes up 9%–39% of 
dementias, though a further 11%–43% may have a mixed dementia with a vascular 
contribution to an Alzheimer‟s picture (18).  The annual incidence of VaD is 3.8/1000 
(18).  Vascular cognitive impairment is a new term, as yet without consensus on 
defining criteria, that refers to VaD and other cognitive impairment resulting from 
vascular disease (18,51).  It is associated with stroke and death from stroke (18).  
Patients with cognitive impairment or dementia resulting from vascular disease 
represent an important group as vascular disease has the potential to be prevented and 
treated (10,18). 
 
VaD itself is a broad term that has many causes, including large and small vessel 
disease, and embolism (52,53).  The most common subtype is cSVD which accounts for 
36%–37% of VaD (49,54).  This group has a much more homogeneous clinical picture 
than other subtypes (5).  cSVD incorporates the concepts of Binswanger‟s disease, 
which is dominated by WML, and the lacunar state, which is dominated by lacunes, 
both of which have been shown to be aetiologically and clinically similar (7,55). 
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1.1.7 Pathology of cSVD 
In order to understand the pathology of cSVD and its propensity to affect certain brain 
regions, it is helpful to consider the relevant normal anatomy of the cerebral 
vasculature.  Large cerebral arteries lead off the circle of Willis and branch into pial 
arteries on the surface of the brain, which give off penetrating arteries that supply the 
deep brain structures (20,21,56).  These are end-arteries with no collateral supply (21).  
The white matter is supplied by distributing vessels that branch off perpendicular to the 
penetrating vessel (20).  Each distributing vessel irrigates a single cylindrical metabolic 
unit (21).   
 
Ageing is associated with particular changes in the cerebral blood vessels, namely 
tortuosity and narrowing of the lumen (13).  Tortuosity refers to the lengthening, 
twisting and coiling of the vessels, which increases the minimum BP threshold 
necessary to maintain perfusion (13).  The deep white matter is supplied by long 
penetrating arteries, which are particularly affected by this tortuosity, and it is thus 
vulnerable to hypoperfusion, even at „normal‟ pressures in the elderly (13).  Senile 
arteriosclerosis begins towards the end of the fourth decade and leads to thickened walls 
with progressively stenosed lumens (7).  Hypertension can exaggerate the 
arteriosclerotic changes (7).   
 
A grading system exists for arteriosclerotic microvascular disease (57): 
I. Increased tortuosity and irregularity in small arteries and arterioles 
II. Progressive sclerosis, hyalinosis, lipid deposits, loss of vascular wall smooth 
muscle and lacunes: 
a. Old small infarcts 
b. Old haemorrhages 
c. EPVS 
III. Multiple lacunes, diffuse WML, fibrotic thickening of vessel wall with „onion-
skinning‟ 
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The pathological evidence for cSVD is relatively weak.  Since Fisher‟s meticulous 
dissections in the 1960s, there have been few studies of this type (4).  Lacunar strokes 
are rarely fatal and so post mortem examination may lag years after the initiating events 
leading to infarction (4,58).  Furthermore, cSVD requires more detailed dissection of 
the perforating arteries than is routinely performed at autopsy (4).  In a small series of 
pathological studies, involving mostly asymptomatic lacunes often months or years after 
the acute event, in a small number of patients (59), Fisher suggested two distinct 
vascular pathologies other than embolism as the cause of most lacunes (2,4,33).  The 
first is intracranial atherosclerosis, which involves occlusion of a penetrating artery by 
an atheromatous plaque (2,33).  The second he named “segmental arteriolar 
disorganisation”, which encompasses lipohyalinosis and fibrinoid necrosis (48).  
Lipohyalinosis is characterised by disorganisation and thickening of the arterial wall 
with either luminal narrowing and subsequent occlusion leading to lacunar infarction or, 
with damage to the wall resulting in microaneurysms and haemorrhage (4,7,33,58).  
Fibrinoid necrosis, associated with severe hypertension, refers to narrowing, dilatation 
and necrosis (7).  These hypertensive arteriopathies are thought to lead to either vessel 
occlusion and complete infarction or, to hypoperfusion, ischaemic injury and WML (7). 
 
However, Wardlaw et al. (4) apply different interpretations to Fisher‟s pathological 
findings.  They hypothesise that cSVD may be the result of dysfunction of the blood-
brain barrier (BBB).  They argue that microvascular endothelial damage and 
dysfunction, perhaps as a result of hypertension, might allow toxic substances in the 
blood to enter the arteriolar wall and subsequently the brain interstitial space.  Resultant 
thickening and disorganisation of the arteriolar wall might further reduce the barrier to 
said toxic substances, and lead to direct damage to the neural tissue (4).  CBF might 
then be reduced either due to luminal narrowing or secondary to damaged neural tissue 
(4).   Farrall and Wardlaw (58) recently reviewed, and performed a meta-analysis upon, 
papers investigating the BBB in ageing and microvascular disease.  BBB permeability 
was seen to increase with normal ageing, further in patients with VaD, and also in 
patients with a larger WML load (58).   
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There are three limitations to the findings of Farrall and Wardlaw (58) that ought to be 
noted.  There were no studies of BBB permeability in patients with lacunar stroke, nor 
indeed, probable cSVD (other causes of lacunar stroke having been excluded).  The 
reviewed papers did not all report congruent results, though where significant findings 
from the meta-analysis were presented, the majority of papers evidently did agree.  
Finally, although the reviewed evidence shows increased BBB permeability, it does not 
follow that this is the causative process.  Farrall and Wardlaw (58) have tried to address 
this last issue, citing evidence derived from an animal model.  Sironi et al. (60) describe 
a spontaneously hypertensive stroke-prone rat that develops a cerebral microvascular 
disease similar to the human cSVD, in which the initial brain abnormality is leakage of 
plasma components across the BBB into perivascular tissue.   
 
There is a rapidly growing body of evidence associating BBB dysfunction with cSVD, 
reviewed recently by Professor Wardlaw (44).  However, it is not yet clear whether 
BBB dysfunction is the cause or result of cSVD.  
 
The neurological deficit associated with a LI often progresses over the first 24–36 hours 
(1,61).  Such progression occurs more often with infarcts situated in the basal ganglia 
(40%) and brainstem (50%) compared to those in white matter (9.5%) (61). This 
possibly relates to the lower density of glutamatergic neurons in white matter (61).  
High glutamate and low gamma-aminobutyric acid (GABA) concentrations in blood 
within 24 hours of the onset of stroke symptoms are a strong predictor of subsequent 
neurological deterioration (61).  On the basis of these two findings, Serena et al. (61) 
hypothesised that glutamate, released in high concentrations into the infarct core and 
surrounding penumbra, has a neurotoxic effect resulting from a massive influx of 
calcium ions initiating cell death.  This is compounded by the reduction in the 
neuroprotective GABA concentrations, which would normally increase chloride influx 
to counterbalance the effects of glutamate during cerebral ischaemia (61).  Interestingly, 
that same observation of LI progression is cited by Wardlaw et al. (4) as evidence of 
leakage of the blood-brain barrier. Another possible explanation for progressive 
neurological deterioration following lacunar infarction is inflammation (62,63). 
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1.1.8 Diagnosis of cSVD 
As previously discussed, the diagnosis of cSVD is complex.  Roman (7) presents the 
following brain imaging criteria for subcortical ischaemic vascular dementia, which is 
caused by disease of the small arteries and hypoperfusion:  extensive WML or multiple 
lacunes, in the absence of haemorrhages, cortical and non-lacunar territorial infarcts, 
watershed infarcts, normal pressure hydrocephalus, or specific causes of WML.  
O‟Sullivan et al. (10) use a combination of radiological findings with a history of 
lacunar stroke to ensure a homogeneous study group with cSVD.   
 
1.1.9 Risk factors for cSVD 
The risk factors associated with cSVD include increasing age (7), hypertension (7,64), 
diabetes mellitus (7), smoking (7), and systemic inflammation (65,66).    
 
Fisher believed lacunes to be particularly associated with hypertension, defined as BP > 
140/90mmHg, which he observed in almost 90% of cases (33).  Contemporary research 
however indicates that hypertension, though important, might not be responsible to the 
extent that Fisher postulated.  Jackson and Sudlow (59) performed a meta-analysis on 
studies of risk factors for lacunar strokes and came to the conclusion that they have a 
very similar vascular risk profile to other ischaemic stroke subtypes.  Atrial fibrillation 
and carotid stenosis were associated with non-lacunar infarcts to a greater extent than 
with LI, but no other risk factor, including hypertension and diabetes, was significantly 
different (59).   
 
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) is an inherited form of cSVD that results in 
subcortical strokes and VaD (34).  A number of other uncommon genetic causes of 
cSVD are being recognised (67,68). 
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1.1.10 Management of cSVD 
The evidence for the management of cSVD is limited by the lack of distinction of the 
underlying aetiology of included patients, for example the failure to separate patients 
with cSVD from those with multi-infarct dementia in the analysis of results.  
 
The management of cSVD falls broadly into two areas: prevention and treatment.  
cSVD has an insidious progress.  Thus it is likely that many patients would not be aware 
that they have the disease and so not present themselves to the health services until they 
have a stroke, marked cognitive impairment, or changes in gait.  This is compounded by 
the difficulties in accurate clinical diagnosis which is often not straightforward, 
especially without brain imaging.   
 
However, many individuals will already have been receiving preventative management 
in the form of modification of cardiovascular risk factors.  This should involve lifestyle 
advice on smoking cessation, diet and exercise (1).  The evidence for drug treatment for 
the prevention of cSVD itself is sparse.  There are several studies of preventative 
treatment of ischaemic stroke in general, however, from which conclusions must be 
cautiously derived for cSVD, in lieu of specific evidence.  The Systolic Hypertension in 
Europe (Syst-Eur) trial found a reduced incidence of dementia with antihypertensive 
treatment (69).  Similarly, the large Perindopril Protection Against Recurrent Stroke 
Study (PROGRESS) is a randomised controlled trial (RCT) that showed that active 
treatment to lower BP reduces the risk of dementia and cognitive decline associated 
with recurrent stroke (70).  The risk of stroke was reduced in both hypertensive and 
non-hypertensive patients with a history of previous stroke or transient ischaemic attack 
(71).  A separate report from the same trial found that reducing BP in those with a 
history of stroke did not increase the risk of silent brain infarcts or atrophy (72).  
Although evidently beneficial in the majority of patients with vascular risk factors, 
concern remains that reducing BP might have a negative effect in patients with cSVD 
(21).  Furthermore, a Cochrane review came to the conclusion that lowering BP in 
hypertensive patients without prior cerebrovascular disease had no benefit in preventing 
cognitive decline, though many of the controls ultimately received antihypertensive 
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treatment too (73).  One of the reviewed studies did, however, provide data on distinct 
stroke sub-types and showed a reduced incidence of first-ever lacunar strokes (74).  
Interestingly, a small study of 12 patients with a radiologically-confirmed lacunar stroke 
found that VMR was significantly increased after treatment with Perindopril for two 
weeks (75), which might suggest a potential benefit of antihypertensive therapy in 
cSVD.  Cerebral VMR is the process of provision of adequate cerebral perfusion in 
response to a functional demand, by vasodilatation of cerebral arterioles leading to a 
reduction in the resistance of the vascular bed and consequent increase in local CBF 
(76).  Impaired VMR indicates the reduced capability to carry out this process in 
response to a vasodilatory stimulus, such as nitric oxide (NO) (76). 
 
Despite its widespread use, a Cochrane review found no RCT providing evidence for 
the use of aspirin in VaD (77).  The CHS found that the regular use of aspirin was 
associated with an increased risk of ischaemic stroke in women and haemorrhagic 
stroke in both sexes (78).  Two limitations to this observational study ought to be noted.  
Firstly, aspirin users did not necessarily have cardiovascular risk factors and, secondly, 
the authors suggest that the reasons for aspirin use might have confounded the results.  
 
The evidence for the use of lipid lowering therapy is not convincing.  Reports from the 
CHS suggest that statin use slightly reduces the risk of cognitive decline (79) but not 
dementia (80).  The Pravastatin in elderly individuals at risk of vascular disease 
(PROSPER) RCT found no improvement in stroke risk or cognitive function with statin 
use (81).  In a study of 94 patients with a recent lacunar stroke, no improvements were 
seen in cerebral VMR or endothelial dysfunction of the carotid and brachial arteries 
after three months (82).  Conversely, other large studies have found a reduction in 
dementia (83) and stroke (84) risk with statin use.  Statins clearly have a benefit in other 
cardiovascular disorders, which share common risk factors with cSVD (84). 
 
Patients with cSVD may come to the attention of health services with a lacunar stroke 
or cognitive dysfunction/ dementia.  In the acute setting thrombolysis should be 
considered in patients presenting with lacunar stroke if indicated clinically (85).  
26 
 
Aspirin and dipyridamole are also recommended (86).  One study has also found benefit 
in functional outcome, though not mortality, with the administration of intravenous 
magnesium following an acute lacunar stroke (87).  Large RCT are necessary to confirm 
this benefit.  Subsequent management involves multidisciplinary rehabilitation (6) and 
secondary prevention as discussed above.  A patient with an identified cause for the LI, 
for example atrial fibrillation or carotid stenosis, ought to be treated appropriately.  
 
Cochrane reviews have found no consistent evidence in VaD in support of cognitive 
rehabilitation and training (88), memantine (89) or galantamine (90).  However, 
donepezil has been shown to improve cognitive function, clinical global impression 
(which reflects symptom severity and treatment response) and activities of daily living 
in patients with vascular cognitive impairment (91).  Nimodipine has also shown some 
benefit in the short-term in cognitive function and clinical global impression, in patients 
with dementia due to cerebrovascular disease (92).  A small study investigating the use 
of rivastigmine in patients with probable VaD found it to be associated with 
improvements in attention, executive function and activities of daily living (93).  
 
1.1.11 Prognosis of cSVD 
LI were previously considered to have a very benign course, with a low mortality rate, a 
good prognosis for recovery, and a low recurrence rate (1,61).  This belief was based on 
short-term follow-up studies.  Within the first year there is a much lower mortality rate, 
ranging from 2%–15% (2),  as well as less disability, than for other ischaemic stroke 
subtypes, presumed to be due to the smaller infarct size of a LI (1,2).  A rapid recovery, 
resulting in a reduced risk of secondary complications, as well as fewer cardiac co-
morbidities in lacunar patients, are also thought to contribute to the low 1-year mortality 
rate (2).  
 
However, recent studies with a longer follow-up suggest that LI do not have such a 
benign course (2,94,95).  The 5-year mortality rate for LI ranges from 14%–38% (96-
99).  The large difference can be explained by the average age of participants, with 
studies recruiting younger patients portraying more favourable mortality statistics.  
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However, by 10 years after the stroke event between 54% (97) and 60% (98) of patients 
had died. 
 
The risk of a recurrent stroke increases from 7.7% at 1 year, to 22.4% at 4-5 years (2).  
Factors that predict a subsequent stroke include vascular risk factors, the severity of 
cSVD, a cardioembolic source, diabetes with concomitant hypertension, and diabetes 
with silent lacunes (2).  The progression of apparently asymptomatic cSVD is much 
more likely than a new stroke, and is thought to insidiously impair brain function (1,2).  
 
Ten years on from a symptomatic lacunar stroke, less than a third of patients are still 
alive and free from recurrent stroke (2).  Of the survivors, many are disabled or 
cognitively impaired (2).  There is good evidence then, that although the initial 
prognosis for a LI is comparatively good, in the long term there is an increased risk of 
death, stroke recurrence and cognitive impairment. 
 
 
1.2 Cognitive disturbances in cSVD 
O‟Sullivan et al. (9) have shown that disturbance in cognition can be used as an 
objective clinical measure of discriminating patients with cSVD and suggest its use as 
an outcome measure in clinical trials.  The most commonly recognised feature of 
impaired cognition associated with cSVD is executive dysfunction (5,9).  Attention and 
the speed of information processing are also impaired, whilst memory is relatively 
spared (5,52,53).  In contrast Alzheimer‟s disease, the predominant cause of dementia, 
has a cognitive profile dominated by problems with memory (18). 
 
In VaD pathological changes such as WML, impaired VMR and altered resting CBF are 
most evident in the frontal lobes (49).  Executive function is a component of the frontal 
cortical areas, in particular the dorsolateral prefrontal cortex (52,100).  It encompasses 
higher cognitive processes, such as planning, attentional set shifting, the selection of 
appropriate responses and working memory (9).  Working memory refers to the ability 
to temporarily store and manipulate information required for the task in hand, and is 
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separate from episodic or long term memory (9).  Regardless of other deficits, executive 
dysfunction results in morbidity, dependence, and an increased need for care (50).   
 
As to be expected from their shared aetiology (cSVD), LI and vascular cognitive 
impairment are closely linked (9,54).  Cognition declines in the period immediately 
following a LI, and there is an increased risk of cognitive decline leading to dementia, 
in the long term (54).  Lacunes are thought to contribute to neurological damage which 
results in vascular cognitive impairment (54).  Both pathologically and radiologically, 
lacunes, as well as WML (LA), are observed in patients with VaD (52,53).  Discrete 
lacunes were reported in 93% of patients with VaD (18).  Aharon-Peretz et al. (101) 
found 83% of those with lacunes and LA to have cognitive impairment.  However, they 
also found the progression to frank dementia to be slow.  This finding might be biased 
by the use of dementia screening tools that are based upon an Alzheimer-type dementia 
(9).  The cognitive profile associated with VaD is quite distinct from that of 
Alzheimer‟s disease.  Thus an individual with cSVD may have accumulated very severe 
cognitive impairment before being recognised as having dementia, when using such 
screening tools. 
 
Lacunes and VaD tend to be diseases of older people.  Changes have been noted in the 
cerebral vasculature of non-diseased older people.  Schroeter et al. (102) noted a drop in 
the haemodynamic response in the frontal lobes during a colour-word matching Stroop 
Interference Task („Stroop Task‟) (103), in elderly versus young individuals.  
Histological studies have shown alterations in the organisation of cerebral small vessels 
associated with increasing age (104).  
 
Older age is associated with a progressive decline in cognitive function (105).  
O'Sullivan et al. (105) postulate that this might be a consequence of “structural 
disconnection” due to disrupted white matter tracts, rather than dysfunctioning grey 
matter regions, as evidenced by a post-mortem study (106) and by diffusion tensor 
imaging (DTI), an MR technique used in their study.  They propose that NO might lead 
to the activation of microglia, which are involved in myelin phagocytosis, resulting in 
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the reduced number of myelinated white matter fibres apparent in normal ageing.  The 
hypothesis of structural disconnection has also been applied to cognitive impairment in 
cSVD (10).  cSVD might expedite these age-related changes (49). 
 
The presence of cSVD-associated lesions on MRI predicts cognitive dysfunction (107).  
However, structural markers of cSVD, such as T2 lesion volume (5,10), LA (51) or the 
number of lacunes (5,108,109), do not actually correlate well with clinical or cognitive 
impairment (5,10,109-113).  They may represent the end-points of tissue damage (113).  
Alternative MR techniques promise to offer a better measure of the problems associated 
with cSVD.  This study aims to identify better and more quantitative markers of cSVD.    
 
In the ensuing chapters, the literature surrounding the use of imaging markers in cSVD 
shall be systematically reviewed and basic MRI theory touched upon, before a 
discussion of the functional MRI techniques used in this study.  Chapters 4 and 5 shall 
detail the methods and results and lead on to a discussion of the findings and their 
implications. 
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Chapter 2: Review of imaging markers of cSVD 
 
VaD is a heterogeneous disorder that is not consistently classified.  Lopez et al. (114) 
applied three different sets of VaD classification criteria to a set of patients from the 
CHS, none of which selected the same group of patients.  Like VaD, LI also have 
multiple causes. However, cSVD is the predominant cause of both and is a much more 
homogeneous disorder.   
 
Small cerebral vessels 20–40µm in diameter cannot be directly visualised in vivo (8).  
cSVD can be identified by meticulous and laborious pathological dissection, as 
demonstrated by Fisher (33).  However this is neither practical, nor does it allow pre-
mortem diagnosis.  The advent of brain imaging with computed tomography (CT) and 
MRI has brought a renewed interest to this disease process.  These imaging modalities 
are able to demonstrate the end-organ damage of cSVD.  Two main lesions are visible, 
LA and lacunes.  There is much debate as to whether LA and lacunes correlate with 
cSVD progression.   Indeed LA (14) and lacunes (96) are commonly seen in apparently 
healthy elderly subjects.   
 
By charting the progression of cognitive decline it might be possible to delineate the 
progression of cSVD.  Cognitive decline might also act as a suitable outcome measure 
for clinical trials.  However, repeated cognitive tests are subject to a learning effect, are 
influenced by mood and motivation, and are time consuming (10). Such tests are also 
influenced by pre-morbid intelligence (115).  Imaging markers may offer a more 
objective and consistent measure of cSVD severity.  Various markers have been 
suggested, including both structural changes such as LA, and functional changes such as 
CBF.  However, there is considerable discrepancy in the available evidence.  Thus, a 
literature review was performed with the aim of attempting to clarify the evidence for 
and against each imaging marker.  A meta-analysis was not performed because of the 
inconsistency in the type of outcome data, such that aggregation of results would not be 
possible.   
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The databases Medline (via Ovid), Web of Knowledge, PsycINFO, SCOPUS, Science 
Direct, AMED- Allied and Complementary Medicine, CINAHL, the Cochrane Library, 
ebrary, TRIP database, Bandolier and Intute: medicine, were searched for relevant 
clinical trials.  Search terms included „cerebral small vessel disease‟, „cerebral 
microangiopathy‟, „cognitive dysfunction‟, „imaging marker‟ and „NOT CADASIL‟.  
Selected papers were limited to English clinical trials published before May 2009.  
Further studies were identified from the reference lists of papers highlighted. 
 
Only trials that selected a patient group with probable cSVD were included.  The trials 
also needed to have a neuropsychological test as an outcome measure to allow 
comparison of results between papers.    
 
Nineteen studies were identified that had reasonably well-defined patients with cSVD.  
The main characteristics of the included studies are presented in appendix A.  The 
interventions investigated included standard structural MRI, magnetic resonance 
spectroscopy (MRS), DTI, diffusion weighted imaging (DWI), CT, single photon 
emission computed tomography (SPECT), positron emission tomography (PET), 
functional near-infrared spectroscopy (fNIRS) and post mortem examination.  
Surprisingly, no studies of microbleeds as an imaging marker were identified that met 
the entry criteria. 
 
 
2.1 WML 
WML and their correlation with cognitive dysfunction have already been extensively 
reviewed (13,15,20).  There is a huge body of evidence both for and against any such 
correlation.  However, the majority of the identified studies with strict criteria for the 
selection of patients with likely cSVD found no correlation between LA and cognitive 
dysfunction (5,10,49,113).   
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Appelros et al. (96) found MMSE score at both baseline and 5 years to correlate with 
WML score at both baseline and 5 years.  However, the decline in MMSE score was not 
associated with an increased WML score, nor indeed with the WML score at baseline or 
5 years.  These results suggest that cSVD is associated with both LA and with cognitive 
dysfunction, as it is known to be, but that LA and cognitive dysfunction are not 
themselves directly linked.  A change in one does not directly induce a change in the 
other.   
 
Wen et al. (116) found LA to be independently associated with executive dysfunction, 
as measured by the Mattis Dementia Rating Scale-Initiation/ Perseveration sub-scale 
(MDRS-I/P).  However, when the quartile with the most severe lesions was removed 
from analysis, the association disappeared.  The authors suggest a „threshold 
hypothesis‟, whereby WML only exert an effect upon executive function when they are 
sufficiently severe (116).  This relationship does not lend itself to a suitable surrogate 
marker of clinical severity, where a linear correlation would be best. 
 
Finally, Mok et al. (117) found WML volume to predict MDRS-I/P score, amongst 45 
patients with LA and a lacunar stroke.  There was no healthy control group.  Patients 
had had a lacunar stroke, though whether this was a clinical event or a LI is not clear.  
Although 111 imaging variables were compared to MMSE and MDRS-I/P tests, there 
was no evidence of any statistical correction for the multiple comparisons. 
 
 
2.2 Lacunes 
Similarly to WML, the overwhelming majority of studies of well-selected patients with 
cSVD found no evidence for an independent correlation between cognitive impairment 
and site, number or volume of lacunes (5,49,113,116,118-122).  However, three studies 
have found a link between the presence of lacunes in either the basal ganglia (96,123) or 
thalamus (121,123) and cognitive impairment.  Only one of the three papers correlates 
the site-specific lacune with a measure of executive function (MDRS-I/P) (121).   
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It is worth noting that a „strategic infarct dementia‟ is a well-recorded entity, resulting 
as the name suggests, from an infarct in an area of the brain important for a particular 
function (7,124).  Although a strategic infarct might conceivably account for the 
observed cognitive impairment, it is a rare event, with basal ganglia and thalamic 
associated strategic infarct dementias accounting for 4.6% of VaD cases (125), and as 
such might be considered unlikely to be the sole reason.   
 
Appelros et al. (96) found patients with a high basal ganglia score to exhibit lower 
MMSE scores, but there was no correlation on longitudinal analysis.  The study by Gold 
et al. (123) was an autopsy-based study of 72 patients.  However, 29 of those patients 
had cortical infarcts and were included in the analysis.  Although 16 of the 72 patients 
had likely cSVD, these were not analysed separately, and thus the findings of this paper 
cannot be assumed to be related to patients with likely cSVD.  Mok et al. (121) found 
the presence of thalamic lacunes to be independently associated with both the MMSE 
and MDRS-I/P, in an uncontrolled sample.  Likewise with the relationship between LA 
and cognitive dysfunction, it is not surprising to find the presence of lacunes to be 
associated with cognitive dysfunction, as both are associated with underlying cSVD.  
However, the presence of lacunes provides just two groups, those with and those 
without.  It provides nominal data, which is a poor marker of changing severity, when 
compared to the ordinal data of a scale such as the MDRS-I/P.   
 
In summary, there is no convincing evidence for an association between cognitive 
impairment and the number or volume of lacunes.  There is limited evidence to suggest 
that the site of a lesion might affect the severity of impairment, but this could not be 
used to chart the progression of disease in an individual. 
 
 
2.3 Atrophy 
The evidence for an association between brain atrophy and cognitive impairment is 
compelling (5,10,96,113,117,121,126).  In two cases the link disappeared on 
multivariate analysis (10,121) and one paper did not find a significant association, but 
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did report a trend towards such (p > 0.05) (120).  Cerebral atrophy correlates well with 
neuropsychological impairment, but it is not specific for cSVD (127) and might 
represent a point at which intervention is too late to effect much change. 
 
 
 
 
 
 
2.4 DTI measures 
Three studies have investigated DTI in patients with cSVD that fit the entry criteria, and 
all showed very promising results, though all are from the same study institution 
(5,10,128).  Exemplary selection criteria and neuropsychological tests are used.  DTI is 
used to detect white matter tract integrity (10).  The studies lend evidence to the 
“disconnection syndrome” theory, which describes cognitive impairment in cSVD as 
resulting from disruption of white matter tracts that form cortical-subcortical and 
cortical-cortical connections (10).   
 
Figure 4: Axial view of T1-weighted images from two individuals, one with (right) and 
one without (left) evidence of cerebral atrophy. 
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Larger studies by other institutions are necessary to confirm the correlation between 
DTI measures and cognitive impairment.  It is not clear whether there is an overlap of 
study participants amongst the three studies. 
 
 
2.5 MRS 
MRS is used to non-invasively estimate brain metabolite concentrations (129).  Van 
Zandvoort et al. (130) found relative concentrations of N-acetylaspartate (NAA) (as a 
ratio of Creatine (Cr)) to be reduced in the normal-appearing white matter of the 
centrum semiovale.  Hund-Georgiadis et al. (119) found relative concentrations of NAA 
(as a ratio of both Cr and Choline (Cho)) to be reduced in the parietal intact white 
matter.  This reduction in relative NAA concentration was correlated in both cases with 
impaired cognitive functioning.  Reduced NAA suggests axonal damage or neuronal 
loss (119).  In contrast, Nitkunan et al. (129) found no correlation between any 
metabolite measured in the white matter of the centrum semiovale and cognitive 
impairment, although absolute NAA concentration was reduced in patients within 
regions of LA. This is consistent with tissue damage occurring in the visible WML 
rather than in normal-appearing white matter (129).  However, it does not appear to be 
consistent with DTI findings of white matter tract damage occurring in the normal 
appearing white matter (128). 
 
  
2.6 Cerebral perfusion and glucose metabolism 
Yang et al. (131) showed a reduction in CBF in several regions in patients with 
subcortical VaD versus controls, though this did not appear to correlate with dementia 
severity as gauged by the Clinical Dementia Rating (CDR) scale.  The sample size was 
small and though a thorough neuropsychological battery was said to have been done, the 
results were not reported. 
 
Sabri et al. (113) found that both reduced regional CBF and glucose metabolism were 
associated with neuropsychological deficits.  The included patients were well selected 
36 
 
for cSVD, the sample size was comparatively large (57 patients), and a large battery of 
neuropsychological tests were used.   Further studies in patients well selected for cSVD 
are needed to confirm these results. 
 
 
2.7 Amplitude of vascular response to Stroop Task 
A recent fNIRS study by Schroeter et al. (49) found cognitive dysfunction to be 
associated with a reduced and delayed haemodynamic response in patients with cSVD.  
Neuronal activation stimulated by a given task induces a haemodynamic response, 
characterised by a relative increase in blood oxygenation, which can be measured (49).  
This exciting development might be used to measure earlier changes in the cSVD 
process, before end-organ damage such as WML are apparent, increasing the time for 
intervention.  However, the study only included 12 patients, 5 of whom had evidence of 
macroangiopathy.   
 
Functional MRI (fMRI) using the blood-oxygen-level-dependent (BOLD) signal also 
measures the haemodynamic response.  As yet, there are no studies that attempt to 
correlate fMRI findings with cognitive impairment in patients with cSVD.  However, 
one study has noted a reduced rate of rise and maximum rise in BOLD signal in patients 
with a first-ever lacunar stroke, in response to a finger-tapping task (132). 
 
 
2.8 Discussion 
The diagnosis of cSVD is dependent upon the patient having a lacunar stroke, a lacune, 
WML, or a combination of the three.  As the structural markers of cSVD account for 
part of the definition, it is inevitable that these markers will correlate with the disease 
group, when compared with healthy controls without such pathology.  cSVD is 
associated with cognitive impairment, so a patient group is likely to have a greater level 
of such impairment when compared with controls.  However, it does not follow that 
these pathological lesions closely correlate with cognitive impairment, merely that they 
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share a common aetiology.  Thus, an apparent correlation between an imaging marker 
and cSVD might be due to selection bias rather than reflect a true correlation.   
 
It is important to select a well-defined group of patients with cSVD.  It allows a 
statement of any differences noted to be made with confidence, for example that a 
particular marker is a good surrogate marker for cognitive decline in cSVD.  Having 
made this first step with relative certainty, the knowledge gained can be used to 
investigate more diverse clinical groups, such as the elderly or patients with VaD.  
 
There are several reasons for the discrepancies in the evidence and confusion 
surrounding imaging markers for cSVD, summarised in Box 2. 
 
In conclusion, functional markers and DTI appear to show a better correlation with 
cognitive dysfunction than the traditional structural markers of cSVD, LI and WML.  
However, the evidence for these newer markers needs to be corroborated by larger 
studies with more uniform tests of executive dysfunction and strict criteria for cSVD.  
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Box 2: Limitations of research into potential imaging markers for cSVD. 
 
1) Inconsistencies and uncertainties in terminology, definitions and criteria 
a) Inconsistent use of terminology in the literature for cSVD itself.  Other terms 
used for cSVD include CMA and subcortical ischaemic VaD.  However, these 
are not always synonymous. 
b) Inconsistent terminology for lacunes, LI and lacunar strokes (24). 
c) Variable definitions/ criteria are used for VaD and cognitive impairment.  This 
might result in different groups of patients being selected and compared (94). 
d) Variable definitions are used for observed lesions, e.g. a lacune is defined as 
<15mm in some and <20mm in other papers. 
e) Confusion over what constitutes cSVD, for example many authors consider 
WML to be synonymous with cSVD. 
f) Lack of pathological studies. 
g) Other dementing illnesses, particularly Alzheimer‟s disease, may not be 
sufficiently excluded. 
2) Variable measures 
a) Variable scales are used by different researchers.  Some use qualitative 
methods, others semi-quantitative for measuring WML. 
b) Variable measures of cognitive function.  E.g. some trials don‟t use tests of 
executive function, but tests such as MMSE as an outcome measure. 
3) Design limitations 
a) Small sample size. 
b) Lack of a matched control group. 
c) Different populations are used, e.g. general population, dementia, VaD, cSVD. 
d) Often, the independent contributions of different measures are not assessed, 
i.e. by multivariate analysis (114). 
4) Variable time from onset of LI to study participation. 
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Chapter 3: MRI 
 
3.1 MRI Theory 
It is beyond the scope of this thesis to provide detailed information on MRI theory, but 
further information can be found in many of the standard textbooks (133,134).  
However, a brief synopsis of basic MRI theory is provided.  MRI is based upon the 
behaviour of the nuclei of certain atoms, particularly hydrogen atoms (henceforth 
termed protons), when exposed to an external magnetic field.  Protons can be thought of 
as miniature bar magnets.  A spinning proton is a spinning positive charge, which is an 
electrical current, which produces a magnetic field. As such, protons have intrinsic 
magnetisation.  Thus, when placed in an external magnetic field (as provided in an MRI 
scanner), protons will interact with this field. Protons spin about their axis as described, 
but also precess, that is they also turn in a “cone-shaped fashion” (135) around the axis 
of an applied magnetic field (Figure 5).   
 
  a    b 
 
 
 
 
 
 
Figure 5:  Diagram to show the movements of a proton (shown as a thin arrow): spin 
about its axis (a); and precession (b) with the proton shown at three different time-
points.  The vertical block arrow represents the direction of the applied external 
magnetic field. 
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MRI scanners contain a large superconducting magnet.  Protons placed within this 
magnet align themselves along its magnetic field, resulting in a longitudinal 
magnetisation along the z-axis.  A transmitted radio-frequency (RF) pulse transfers 
energy to protons that are precessing at the same frequency and causes the protons to be 
in phase, i.e. to all be in the same position around the precessing cone (Figure 6).  The 
protons also begin to precess (or „tip‟) around the axis of the applied RF pulse (the RF 
pulse is in effect another applied magnetic field). This causes a reduction in the 
longitudinal magnetisation and the induction of a transverse magnetisation along a 
perpendicular axis.  When the RF pulse is switched off the protons return to their pre-
RF pulse state.  There is longitudinal relaxation as the energy provided by the RF pulse 
is transferred from the protons to their surroundings.  This is known as T1 relaxation.  
T1 is the time taken for a tissue to recover 63% of its longitudinal magnetisation.  
Following the RF pulse, there is also transverse, or T2, relaxation, as the precessing 
protons lose phase coherence.  T2 is the time taken for 63% of the induced transverse 
magnetisation to have disappeared.         
 
 
 
   a     b 
 
 
 
Figure 6: Diagram showing protons (each represented by a single arrow) in (a) and 
out of (b) phase. 
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Different tissues have different characteristics.  Water has a long T1 and T2.  In 
comparison to water, fat has a short T1 and T2.  By varying scanning parameters, such 
as the time to RF pulse repetition (TR) or the time to echo (TE), which is the time 
between RF signal transmission and acquisition, different tissue characteristics can be 
highlighted.  A short TR and TE result in T1-weighted images that highlight 
longitudinal relaxation time.  Fluid appears dark on the images.  In contrast, fluid 
appears bright on T2-weighted images, formed using a long TR and TE.  FLAIR (Fluid 
attenuated inversion recovery) sequences enhance the visibility of lesions by 
suppressing the signal from background CSF (136).  CSF signal and the contrast 
between white and grey matter are reduced (136).  This sequence is particularly useful 
for separating WML from CSF-like lesions (137). 
 
Other tissue properties can be exploited to provide different images: the flow of blood 
can be measured using MR-angiography (MRA) or arterial spin labelling (ASL); the 
BOLD signal utilises the deoxyhaemoglobin content of blood; and signal loss due to the 
presence of tissue with high susceptibility such as veins can be detected by 
susceptibility-weighted imaging (SWI).  ASL and BOLD shall be discussed further in 
the next section. 
 
 
 
 
Figure 7: Examples of, from left to right, T1-, T2-, and FLAIR-weighted images. 
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3.2 Functional MRI 
Two main functional techniques will be focused upon:  the BOLD signal and CBF 
measurement using ASL.  A reasonable body of literature has been compiled on each 
individually.  However, they are both techniques still in their comparative infancy in 
terms of development, as borne out by their limited current application clinically.  Used 
concurrently, the BOLD and CBF measurement by ASL might enable a more accurate 
measure of neural activity than either alone.   
 
3.2.1 CBF measurement using ASL 
In healthy individuals CBF changes with varying neural activity levels (138).  Local 
CBF changes induced specifically by a neural task can be used as a marker of changing 
neural activity (138).  There are many established imaging techniques for measuring 
CBF, reviewed recently by Wintermark et al. (139):  SPECT, PET, and MRI with 
contrast, such as gadolinium, are three well known examples.  ASL is a developing non-
invasive functional MR technique that can provide a quantitative measure of resting and 
dynamic CBF (140-149).  All the techniques are based upon a similar principle in that 
they measure the concentration of a contrast material that is delivered in the blood and 
cleared from the tissue of interest (138,150). 
 
ASL uses water as an endogenous, non-radioactive tracer (138).  A magnetic label is 
applied to the water molecules of flowing blood (138).  The rate at which these labelled 
molecules are delivered to an imaging slice is determined by local CBF (140).  The 
magnetic label decays within approximately 1-2 seconds (150).  The short turnover time 
allows rapid repetition and hence dynamic measurements of CBF (150).  Repeated 
scans are also possible with ASL because there is no risk of radiation over-exposure, as 
there is with radioactive tracer techniques (138). 
 
To acquire the labelled image a magnetic label is applied to water molecules by 
inverting or saturating the longitudinal (Z-axis) component of the magnetisation of the 
hydrogen nuclei (or „spins‟) (138).  These labelled molecules enter the capillaries, 
carrying reduced longitudinal magnetisation, so decreasing the average magnetisation in 
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the voxel (a three-dimensional measure of volume).  This manifests as a reduction in the 
T1-weighted signal compared to the control images, in which the blood is already fully 
relaxed (138,151).  The more labelled blood that enters the image slice, the greater the 
signal changes versus the control image (138).  After a delay TI (the inversion time) 
following the labelling of arterial blood to allow for it to have entered the region of 
interest, an image is obtained (138).  A control image, with no labelled blood, is taken 
of the same region to account for the contribution of the static image (138).  
 
Labelled and unlabelled images are alternated (150).  The difference of these paired 
images is used to measure CBF (138).  A series of paired images are usually taken, and 
averaged, to account for the inherently low signal-to-noise ratio (SNR) and to produce a 
map of CBF (152). 
 
One reason for the inherently low SNR is the necessary short inversion time 
(approximately 1 second), due to the short lifespan of the label T1, allowed for labelled 
blood to arrive in the region of interest (138).  In this time, about 1ml of blood is 
supplied for every 100ml of tissue (138).  Thus the tagged blood only makes up roughly 
1% of the total MR signal from the tissue, resulting in a low SNR (138). 
 
There are different types of ASL, which label the arterial blood based on location 
(Pulsed ASL), velocity (Velocity-selective ASL) or both (Continuous ASL) (138). 
 
ASL has been validated in healthy subjects using dynamic susceptibility contrast (153) 
and with 
15
O-PET at rest (154) and with activation (155).  It has also been validated for 
measuring CBF in patients with cerebrovascular disease (156-158). 
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3.2.2 BOLD signal 
The BOLD signal is an indirect marker of neural activity (159).  As the name suggests, 
it is a signal produced according to differing levels of oxygen in the blood.  In fact it 
depends upon the deoxyhaemoglobin concentration in venous blood (160).  
Oxyhaemoglobin is diamagnetic, whereas deoxyhaemoglobin is slightly paramagnetic 
(159,161).  This property of deoxyhaemoglobin means that it induces microscopic 
magnetic field inhomogeneities around it, which can be picked up using MRI as a drop 
in the T2* relaxation time, and hence a reduction in the MRI signal (141,161). 
 
The changes in deoxyhaemoglobin concentration result from the „haemodynamic 
response‟ to neural activity (141).  The haemodynamic response has three main 
components: changes in CBF, cerebral blood volume (CBV), and the metabolic rate of 
oxygen consumption (CMRO2) (141,159).  Increased neural activity is associated with a 
seemingly paradoxical drop in deoxyhaemoglobin, which in turn leads to reduced 
magnetic field distortion and hence to an increased BOLD signal (141,159).   
 
 
 
 
Figure 8: Diagram of BOLD signal, for a stimulus of duration 30 seconds. 
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Matthews and Jezzard (161) succinctly describe the relationship between neural activity 
and a measurable BOLD signal, expanded upon here.  Neural activity uses energy, 
which is thought to be mostly needed for postsynaptic neuronal depolarisation.  This 
results in the uptake of oxygen and hence the increase in deoxyhaemoglobin, which is 
assumed to cause a contentious early dip in the BOLD signal, contentious as the dip is 
not always seen (162).  Blood flow to the area increases.  There has been great debate as 
to whether the drop in oxygen or glucose drives the increased blood flow.  Current 
opinion holds that it is neither, but rather a result of local signalling (142,161).  
Nevertheless, the increased blood flow provides the substrates needed for energy 
metabolism.  However, the blood flow increases to a greater extent than is needed 
merely for substrate provision.  Due to the metabolic demands of neural activity, more 
oxygen is taken from the blood than in the resting state, but the proportion of oxygen 
taken from each unit of blood decreases because of the increased flow.  In other words, 
there is a drop in the oxygen extraction fraction, which manifests as a smaller 
concentration of deoxyhaemoglobin relative to oxyhaemoglobin in the area of neuronal 
activation.  This, in turn, is detected as an increase in T2* relaxation time and hence the 
production of an increased BOLD signal.  
 
 
Figure 6: Summary flow chart of events leading to BOLD signal. 
 
Figure 9: Su mary flow chart of events leading to BOLD signal. 
Stroop task 
Neural activity 
 
↑ Oxygen uptake  
↑↑CBF 
↑Oxy-Hb:Deoxy-Hb 
↑BOLD 
signal 
 
↑ Glucose uptake  
↓ OEF 
Initial ↑ in Deoxy-Hb 
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The BOLD signal is complex.  It „measures‟, albeit indirectly, the averaged neural 
activity of an area and thus could represent a small change in a lot of neurons or a large 
change in a few (162).  Sub-threshold activity, excitation, inhibition, or modulatory 
inputs might all contribute to the BOLD signal (76,162).  Logothetis et al. (163) 
maintain that the BOLD signal reflects the “input and intracortical processing” of an 
area.  Regardless of what exactly constitutes the BOLD signal, the magnitude of the 
BOLD response can be altered by MRI specific parameters, for example magnetic field 
strength (164).  
 
Although a complex signal, it is still a useful marker of neural activity, with good 
agreement observed between amplitudes of fMRI and electroencephalography (EEG) 
(161,165,166).  Logothetis et al. (163) show a proportional link between the BOLD 
signal and the average level of neuronal activation.   
 
BOLD signal is a measure of the haemodynamic response, rather than a direct measure 
of neural activity.  The use of the BOLD signal as an indirect marker of neural activity 
is dependent upon neurovascular coupling (NVC), the concept that a predictable 
haemodynamic response follows increased neural activity (56).  In clinical studies, 
particularly those investigating cerebrovascular disease, this response might be altered 
(56).  Thus any difference seen in the BOLD amplitude seen for example between a 
normal and a clinical group might not reflect neural activity, but impaired NVC.  Apart 
from cerebrovascular disease such as stroke, increasing age and medication may affect 
NVC.  By altering the haemodynamic response, causing changes in CBF, baseline 
CBV, or the baseline oxygen extraction fraction, there might be changes in BOLD 
signal measurements that are not due to neural activity (167).   
 
Neural activity can be induced by giving a subject a task.  By matching the time course 
of the BOLD signal with that of the task, areas that show changes in activity (changes in 
BOLD signal) as a result of the function can be observed (161).  However, BOLD fMRI 
can only detect relative (i.e. qualitative) signal intensity changes (161).  It is thus mainly 
used as a mapping tool (159).  ASL, on the other hand, can provide quantitative 
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measures of CBF (161).  ASL can be used to simultaneously measure BOLD and CBF 
(159), and the BOLD signal can then be calibrated against the absolute CBF 
measurements (161).  With the inclusion of an additional isometabolic calibration scan, 
some of the neural and vascular components of the BOLD response can be separated, 
allowing the estimation of the change in CMRO2 (138), which is thought to be closely 
linked to neural activity (167).  In this way an insight into the relative vascular, 
measured by CBF change, and neural, by CMRO2 change, contributions might be 
achieved (141).  Thus, Buxton et al. (159) suggest a „measure‟ of neurovascular 
coupling („n‟) can be made by the ratio ∆CBF/∆CMRO2.  
 
3.2.3 Oxygen calibration 
Carbon dioxide (CO2) has been used to calibrate the BOLD signal (168,169).  The 
patient inspires CO2, resulting in an increase in CBF with little change in CMRO2 (159).  
However, there are drawbacks to this widely used method (170).  It may in fact affect 
CMRO2 (171), it induces breathlessness (172), it is intolerable to infirm or distressed 
patients (170), and it has a regionally varying effect on CBF (172).  In light of these 
problems, Chiarelli et al. (170) have suggested an alternative calibration method for 
quantitative BOLD fMRI, using hyperoxia.  Advantages of the hyperoxia over the 
hypercapnia technique are that hyperoxia is much better tolerated, and for longer 
periods; oxygen is cheap and available; the CMRO2 appears to remain constant in adults 
in response to hyperoxia; and the hyperoxia technique has lower inter-subject and inter-
session variability (170).  However, caution is needed when increasing oxygen delivery 
to patients with COPD (chronic obstructive pulmonary disease) (170).    
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BOLD advantages: 
 High contrast: noise ratio (138). 
 Better temporal resolution (2-4 seconds) than ASL, which relies on pair-wise 
subtraction of temporally adjacent images (173).  However, poor temporal 
resolution compared to that of MEG or EEG (milliseconds) (174). 
BOLD limitations: 
 BOLD signal change can vary substantially between subjects and across 
sessions (175,176) . 
 Complex signal, encompassing CBF, CBV, CMRO2, and magnetic field 
strength.  Any variation in these due to age or disease can confound 
interpretation of BOLD changes (138). 
 Exact location of signal change may not define exactly where the presynaptic 
neural activity is found (163). 
Advantages of ASL over BOLD: 
 Smaller inter-subject variability (177-179). 
 Reduced susceptibility artefact in regions of high static inhomogeneity 
(179,180). 
 More specific functional localisation (138,181,182).  Tjandra et al. (179), in a 
study of 6 patients, suggest that CBF may localise activation more accurately 
as it is more sensitive to changes in the capillary bed local to the activated 
neuronal population than BOLD. 
 Can provide quantitative measures of baseline and functional changes in CBF 
(138). 
Limitations of ASL 
 A fewer number of slices (173). 
 Low temporal resolution (173). 
 Relatively low SNR (173). 
 Less sensitive than BOLD (66,72). 
 
Box 3: Advantages and disadvantages of BOLD and ASL techniques for fMRI. 
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3.3 Aims 
cSVD, leading to stroke and cognitive impairment, is an important pathology, more-so 
in light of an ageing population.  Early and accurate diagnosis might allow development 
of prevention and treatment modalities.  Structural MRI markers have proved 
ineffective in delineating cSVD associated with cognitive decline and might offer little 
more than endpoint markers of disease.  However, alternative developing MR 
techniques offer a promising approach to diagnosis.  This study shall look at two such 
techniques, BOLD and CBF measurement by ASL.  The primary aim is to determine 
whether the neurovascular coupling constant, confusingly denoted „n‟, is reduced in 
patients with cSVD when compared to healthy controls.  Thus the null hypothesis is that 
there is no difference in „n‟ between cSVD and control groups.  If „n‟ does prove to be 
reduced in the cSVD group, a secondary hypothesis to be tested is whether „n‟ 
correlates with tests of cognitive, and especially executive, function.  
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Chapter four: Methods 
 
Approval was obtained from the Cheshire Local Research ethics committee.  All 
participants gave written informed consent.  The study was adopted by the Stroke 
Research Network (SRN), as the Liverpool Lacunar Stroke Study (LILACS). 
 
 
4.1 Subjects 
The „lacunar hypothesis‟ suggests that cSVD, the pathology of which being in situ 
microatheroma or lipohyalinosis but not embolism (183), leads to LI that cause 
particular syndromes, namely those detailed in Box 1 (184).  This hypothesis indicates 
that LI are important markers of cSVD (2).  However, the presence of a lacunar 
syndrome in itself does not necessarily indicate underlying cSVD, as the aetiology in up 
to a third of these patients is embolism or, more rarely, a cause such as arterial 
dissection (1,33,184).  Yet, for the purposes of clinical research, careful selection 
criteria can identify patients with a high likelihood of cSVD, particularly by ensuring 
radiological confirmation of a clinically relevant lacunar stroke and exclusion of other 
stroke aetiologies.  In line with this, criteria based on those used by Markus et al. (185) 
in their online protocol for creating a database of cSVD patients, were formulated.   
 
Patients within one year of diagnosis with a lacunar syndrome were recruited from The 
Walton Centre for Neurology and Neurosurgery, Royal Liverpool University Hospital, 
Broadgreen Hospital, Countess of Chester Hospital, Royal Preston Hospital and 
University Hospital Aintree (UHA).  Dr Emsley, a consultant neurologist
1
, confirmed a 
diagnosis of likely cSVD based upon the notes of potential participants.  Those 
considered appropriate were invited to enrol in the study.  Age-matched healthy controls 
with no history of neurological or vascular disease were recruited from the local 
university population and previous healthy volunteers at Magnetic Resonance and 
Image Analysis Research Centre (MARIARC).  
 
                                                          
1
 Consultant appointment made during the course of the study. 
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Exclusion criteria Reason 
Known significant (≥ 50%) extra- or intra-
cranial carotid or cerebral vessel stenosis 
To exclude subcortical infarcts that were 
not likely to have been caused by cSVD. 
Cardio-embolic source of stroke 
Cortical infarct 
Subcortical infarct > 1.5cm 
Any other specific cause of stroke 
Significant pre-stroke cognitive impairment 
(sufficient to interfere with activities of 
daily living) 
To ensure participants were able to 
complete the study protocol and to 
provide written informed consent. 
Significant pre-stroke physical impairment 
(modified Rankin score > 1, or Barthel 
Index < 95) 
To ensure participants were able to 
complete protocol. 
Contraindication to MRI Safety of participants 
Table 2: Exclusion criteria 
Inclusion criteria Reason 
Written informed consent To ensure patients understand and agree 
to taking part in the research. 
Clinical lacunar syndrome These criteria represent a group of 
patients likely to have cSVD. Appropriate MRI lesion(s) (defined as 
subcortical infarct ≤1.5cm in diameter) 
Aged 18-85  
≥1 month from stroke onset To minimise the influence of short-term 
haemodynamic changes in the acute post-
stroke phase and to avoid acute effects on 
MRI or neuropsychology.  
≤12 months from stroke onset To avoid cumulative effects of cSVD, 
and to ensure that the study findings 
might be useful for prognosis. 
Table 1: Inclusion criteria. 
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4.1.1 Sample size calculation 
Quantitative fMRI has not been used in patients with cSVD before.  Indeed the reality 
of trying to quantitatively measure the BOLD response is a recent one.  Goodwin et al. 
(186) recently used hyperoxia-calibrated fMRI with a modified Stroop Task, reporting a 
reasonable reproducibility in the measurements.  They provide data on the change in 
„n‟, a measure of NVC, across six regions in ten young healthy adults.  The value varies 
across the regions from 2.0 in the primary motor cortex to 3.14 in the right parietal lobe.  
An average change in „n‟ is given, but without a standard deviation needed for sample 
size calculation.  „n‟ was found to be significantly greater in the middle frontal gyrus 
than in the motor cortex, which the authors tentatively attribute to a greater vascular 
responsiveness in the frontal region.  Left and right middle frontal gyri values for „n‟ 
were not significantly different.  In the left middle frontal gyrus „n‟ was equal to 2.83 
with a standard deviation of 1.0.  These data were used to calculate the sample size for 
the current study. 
 
To detect a 25% reduction in „n‟ in patients with cSVD versus healthy controls, it was 
calculated that a minimum of 16 patients (and 16 controls) would be needed, using 80% 
power and 5% significance: 
 
 
 
 
 
 
Where,  
N = number of patients needed  
U = Power; U = 0.84 for 80% power 
V = Significance; V = 1.96 for 5% significance 
σ = Standard deviation 
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µ = Expected mean value of „n‟  
µ0 = Null hypothesis mean value of „n‟ 
 
Sixteen patients seems a small sample.  However, due to the expensive and time-
consuming nature of MRI studies it does not represent a comparatively 
disproportionately small cohort.  Indeed the calculation of „n‟ from the Goodwin paper 
(186) was based upon a sample of just 10 participants. 
 
 
4.2 Neuropsychological tests 
On the day of the scan, subjects had clinical assessments of cognition.  Executive 
dysfunction is the dominant feature of cognitive impairment associated with vascular 
disease.  It is also thought that there might be an age-related decline in executive 
relative to other cognitive functions (9).  O‟Sullivan et al. (9) show that executive 
assessment provides better discrimination of patients with ischaemic leukoaraiosis 
(presumed cSVD) from healthy elderly controls than other established brief assessment 
tools, such as the MMSE.  They also conclude that this form of assessment 
distinguishes age- from disease-related changes, in those aged 50–84 years.  The battery 
of clinical cognitive tests used comprised those tests recommended by O‟Sullivan et al. 
(9) and are detailed in Box 4.  
 
These data will be analysed using a two-tailed Student‟s t-test.  This would be expected 
to show a difference between the two groups: that executive function is diminished in 
the cSVD group.  The difference will then be assessed against the scans to suggest 
which, if any, correlate best with executive impairment. 
 
Patients were also functionally assessed using the National Institute of Health Stroke 
Scale (NIHSS) on the day of the scan. 
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Box 4: Neuropsychological test battery. 
 
 
 
 
 Trail making test 
o Assessment of cognitive set shifting and mental flexibility 
o This has two parts, both of which are timed.  The first part, A, 
involves joining randomly positioned numbered points in the correct 
numerical order.  Part B is similar but has lettered as well as 
numbered points and requires a sequence of 1-A-2-B-3-C etc.  Part B 
contains the executive component of shifting between cognitive sets, 
i.e. between numerical and alphabetical rules.  However, parts A and 
B share non-executive aspects, such as visual scanning and motor 
function.  Thus, subtracting the time for part A from that of B, 
theoretically accounts for non-executive effects.     
 Verbal fluency 
o Assessment of the ability to generate words 
o The subject has one minute for each letter to name as many words as 
possible beginning with F, A and then S.  
 Digit span 
o Assessment of working memory (168,169).  
o Subjects are required to repeat back progressively lengthening lists of 
numbers, first forwards and then in reverse.  The backwards 
component is considered a better test of working memory and hence, 
executive function. 
 DSST 
o Assessment of executive functioning and performance IQ.  
o Digits 1-9 are assigned a unique symbol.  The subject has 90 seconds 
to enter the corresponding symbols for a series of digits, requiring 
shifts between the rules for each digit.  
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4.3 Imaging 
4.3.1 Image acquisition  
A 3 Tesla whole-body MRI scanner 
(Siemens Trio, Erlangen, Germany) was 
used, with an 8-channel head 
radiofrequency coil and a body coil for 
signal collection and transmission, 
respectively.  
 
BOLD and CBF signal were measured 
simultaneously using a QUIPSSII (187) 
ASL sequence.  The MRI acquisition 
parameters for the fMRI scans were: TR (repetition time) 2.13s, TI2 1.4s, TE (echo 
time) 20ms.  Twelve slices of 3.5mm thickness and 0.35mm gap covering frontal and 
motor cortices were taken.  
 
Scan Purpose 
T2-weighted Exclude cortical lesions and measure LA (WML). 
Angiography of carotids and 
circle of Willis 
Exclude intra- and extra-cranial vessel stenosis. 
Calibration – ASL and BOLD To allow calculation of calibration constant „M‟ 
according to Chiarelli et al.(170) 
Stroop Task – ASL and 
BOLD fMRI 
To measure CBF and BOLD, and to allow 
calculation of CMRO2, using the constant „M‟ from 
calibration scan. 
SWI To identify microbleeds. 
T1-weighted Reviewed by a radiologist to exclude cranial 
abnormalities unrelated to cSVD. 
Estimate brain structure volume. 
FLAIR Exclude cortical lesions and measure LA (WML). 
Table 3: List of MRI scans and their purpose. 
Figure 10: Slice coverage. 
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4.3.2 Stimulus paradigm 
A colour-word Stroop Task was used (103).  
Subjects were presented with a black screen 
with two words, positioned above and below 
a white fixation cross (Figure 11).  They were 
required to determine if the meaning of the 
bottom word, written in white ink, matched 
the ink colour of the top word.  Using a button 
box, they answered with the index finger of 
the right hand for „yes‟ and middle finger for 
„no‟.  They were asked to respond as quickly 
and accurately as possible.  The task was self-paced, meaning that the screen would not 
change until a response was registered.  The minimum time between stimuli was 2 
seconds.  There were 8 active blocks of 30 seconds, each followed by 30 seconds of a 
fixation cross on a black screen, resulting in a run time of minimum 8 minutes.  Each 
subject practised 4 blocks outside of the scanner to ensure the task was understood.  
 
4.3.3 Hyperoxia paradigm 
The hyperoxia paradigm was used to calibrate the BOLD signal.  The subject had 2 
periods each lasting 3 minutes of breathing high-flow oxygen through an open mask, at 
a rate of 15L/min.  Each of these periods was preceded by breathing normal air (Figure 
12).  End-tidal oxygen was sampled continuously via a nasal cannula.  A vacuum pump 
(Flowcontrol R-2 vacuum pump) connected the nasal cannula to an oxygen analyser (S-
3A/IO2 oxygen analyser; provided by Applied Electro-chemistry Inc, Pittsburgh, USA).  
The oxygen analyser was calibrated against the oxygen concentration of room air 
(GasMonitor4) before each scan.  Respiratory data was logged at 1ms intervals using 
Powerlab software (ADInstruments, Colorado Springs, USA).  
 
Figure 11: Example slide from Stroop 
task. 
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4.4 Data analysis 
BOLD and perfusion image time series were created in MATLAB (The MathWorks 
Inc, Massachussets) from the ASL images collected during both the hyperoxia and 
Stroop Task runs, using „in-house‟ software (186).   
 
4.4.1 Identifying the active regions of interest 
The CBF and BOLD image time series for each subject were pre-processed using Brain 
Voyager (Brain Innovation B.V., Maastricht, Netherlands).  This involved spatial (full 
width at half maximum (FWHM) 6mm) and temporal (FWHM 10s) smoothing to 
reduce the noise in the data (161), and linear trend removal to remove any linear drift in 
the signal.  The CBF and BOLD images were co-registered to a structural T1–weighted 
image that had been transformed into Talairach space.  The aggregated Stroop Task runs 
of all patients and controls were analysed using a general linear model (GLM).  
Significantly active voxels were highlighted (Figure 13).   
 
The areas of highlighted voxels were identified.  In these regions of interest (ROI) the 
Stroop Task activity resulted in significant (p<0.05; corrected for false-discovery rate) 
differences in the BOLD and CBF time-courses.  In each ROI, a volume approximately 
1cm
3
 was chosen encompassing the site of highest activity.  In each of these, the 
average signal time-course for both CBF and BOLD were recorded for both the Stroop 
Task and hyperoxia runs. 
 
2 min 
 
3 min 
3 min 
O2 15L/min 
3 min 
O2 15L/min 
Figure 12: Hyperoxia paradigm. 
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4.4.2 Quantification of neural and vascular parameters 
The neural and vascular parameters of interest in this study were  the change in (Δ) 
BOLD, ΔCBF, calibration constant „M‟, ΔCMRO2 and the NVC parameter „n‟ 
(=ΔCBF/ΔCMRO2).  The first step, then, was to calculate „M‟ with which the other 
parameters might be computed.  MATLAB was used to extract the end-tidal oxygen 
values for 4 time periods, each averaged over 1 minute: the final minute of each 
hyperoxia and each normoxia period. The corresponding BOLD signal was used from 
the same periods. The model provided by Chiarelli et al. (170) for calculating an 
estimate of „M‟ was used with experimental data substituted in: 
 
 
 
 
Figure 13: Example showing highlighted regions 
of interest in the left and right precentral gyri 
(circled), coronal view. 
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 The subscript „HO‟ refers to the corresponding parameter during hyperoxia, and 
„0‟ at baseline.  Therefore, ΔBOLDHO is the change in the BOLD signal during 
hyperoxia and BOLD0, the baseline value for BOLD signal. 
 A reduction in CBF of 5% during hyperoxia is assumed, based on the work of 
Chiarelli et al. (170).  The assumption is used in preference to measured values 
which have a low SNR and need to be corrected to take into account the altered 
T1 of arterial blood during hyperoxia. 
 [dHb] = the concentration of deoxygenated haemoglobin in the venous 
vasculature.   The [dHb] values were calculated from the end-tidal oxygen 
measurements as described by Chiarelli et al. (170)  A baseline oxygen extraction 
fraction (OEF) of 0.4 was assumed (170).  Furthermore, it was assumed that the 
OEF did not change with hyperoxia (170). 
 α = 0.38.  This value, the Grubb relation, was obtained in previous work by Grubb 
et al. (188) by calculating CBV changes from CBF changes, based on the 
assumption inherent in this model that the system is in equilibrium. 
 β = 1.5.  This value is assumed as in previous work (159,170).  
 M = Calibration constant; it represents the maximum theoretical BOLD signal 
change (170). 
 
Values were calculated for „M‟ in each ROI over both individual hyperoxia periods and 
the mean value of the two combined. 
 
The calibration of the BOLD signal is described in detail by Chiarelli et al.(170).   In 
brief, parts A, C, D and E of equation [1] are calculated from experimental data, with 
which part B can be calculated.  Part D is derived from the end-tidal oxygen data, from 
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which the partial pressure of oxygen is inferred.  Three assumptions are involved in this 
calculation.  Firstly CBV is assumed to not be influenced by a change in pure oxygen.  
Secondly, a baseline value of OEF is assumed to be consistent throughout the brain and 
constant during hyperoxia.  Finally, haemoglobin (Hb) is assumed to be 15g/dL.  The 
saturation of arterial Hb is calculated using the partial pressure of oxygen, and is then 
used to calculate the arterial oxygen content using the species-dependent oxygen-
carrying capacity of Hb.  From this the concentration of deoxygenated haemoglobin in 
the venous vasculature can be derived. 
 
The change in CBF and BOLD were calculated by averaging the time-courses for each 
ROI over the eight stimulation blocks and subtracting the corresponding averaged value 
of the „rest‟ blocks.  These values were calculated on an individual basis in each ROI.  
The model described by Buxton et al. (159) was used to calculate the ΔCMRO2:  
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„n‟ is a measure of the relationship between changes in CBF and CMRO2: 
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0
/
/
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n
        [3]
 
 
The models for oxygen-calibration have been developed in healthy subjects.  This is the 
first study in which the technique has been applied to a population with cSVD.  It is 
thus entirely plausible that the constants and parameters used might not apply to a 
patient population.  These limitations shall be addressed further in the discussion. 
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4.4.3 Assessment of cerebral atrophy and ventricular enlargement  
Coronal T1-weighted images, in the 
anterior commissure- posterior 
commissure (ACPC) plane, were 
exported from BrainVoyager into 
EasyMeasure (©2005 Mike 
Puddephat).  This programme slices the 
brain into regular sections and 
randomly overlays a grid of points on 
to each section surface.  The number of 
points over a structure of interest, e.g. 
the ventricles, are totalled for each 
section and used to calculate the 
volume for that structure in mm
3
.  Total 
brain matter (excluding the 
cerebellum), subcortical matter and grey matter volumes were measured using a grid 
size of 8mm and interval between slices of 15mm.  The volume of the lateral ventricles 
was measured using a grid size of 3mm and interval between slices of 6mm.  In the 
event of a cross seeming to lay over two structures, e.g. the border of white and grey 
matter, the structure in the lower right quadrant of the cross was used.  All measured 
volumes were given as a percentage of whole brain volume, to correct for any general 
difference in brain size which is not relevant.   
 
 
 
 
 
 
 
 
 
Figure 14: Example grid used to measure 
volumes of brain structures with 
EasyMeasure. 
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4.4.4 Assessment of WML 
WML were assessed blind using the rating scale of Wahlund et al. (189).  WML 
visualised on MRI were defined as “ill-defined hyperintensities ≥ 5mm on both T2 and 
... FLAIR images”.  Five regions were rated on a scale of 0-3 for each hemisphere: 
frontal, parieto-occipital, temporal, infratentorial and basal ganglia regions.  A score of 
0 represented no visible lesions, and a score of 3 represented diffuse involvement of the 
region.  The score for each region was summed across right and left hemispheres, 
resulting in a score of 0-6 for each region.   
 
4.4.5 Assessment of microbleeds 
Microbleeds were assessed using the Microbleed Anatomical Rating Scale of Gregoire 
et al.(190).  Microbleeds were defined as “small, round, well-defined, hypointense on 
Gradient Echo T2*; 2-10mm; not well seen on T2.”  Susceptibility-weighted images 
were used rather than gradient echo T2* as they have been shown to have a better rate 
of detection of cerebral microbleeds (191,192).  The number of microbleeds was 
counted for each of 13 regions in both right and left hemispheres: 
 Infratentorial: Brainstem; and cerebellum. 
 Deep: Basal ganglia (caudate and lentiform); thalamus; internal capsule; external 
capsules; corpus callosum; and deep and periventricular white matter. 
 Lobar (including cortex and subcortical white matter): Frontal; parietal; 
temporal; occipital; and insula. 
 
The total number of microbleeds was calculated for infratentorial, deep, lobar and total 
regions.   
 
4.4.6 Angiography 
Stenoses greater than 50% were excluded by an experienced neuroradiologist, using the 
MRA images of the carotid arteries and circle of Willis. 
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4.5 Statistical analysis 
Microsoft Excel and SPSS were used for statistical analysis.  The mean, standard 
deviation and standard error were calculated for all variables.  Patient and control 
groups were compared using a two-tailed Student‟s T-test for all variables.  P-values 
less than 0.05 were deemed significant.  One way analysis of variance (ANOVA) with 
repeated measures was used in SPSS to identify difference between regions of interest, 
where t-test showed a significant difference between patients and controls.  Negative 
values for „n‟, CMRO2 or M were deemed nonsense values attributed to noise and were 
excluded.  Values greater than three standard deviations from the mean were considered 
outliers and also excluded.  Image measures were individually plotted against 
statistically significant cognitive function measures.  Regression analyses were 
performed using the LINEST function in Excel and the probability value of any 
correlation was calculated using the Fisher F-statistic.  
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Chapter five: Results 
 
5.1 Recruitment  
Fifty-two suitable patients with likely cSVD were identified and contacted by letter and 
followed up with a telephone call.  Fourteen individuals agreed to participate in the 
study.  Two were unable to complete the study protocol, one due to arthritis and the 
other due to claustrophobia.  A further participant was excluded because of a space 
occupying lesion observed on MRI.  Thus the data were derived from the eleven 
remaining patients.  One of these did not have the hyperoxia calibration scan due to 
COPD.  As a result ∆CMRO2, M and „n‟ could not be calculated for this subject.  
Sixteen age-, sex- and education-matched healthy controls were also recruited. 
 
Figure 15: Chart to 
demonstrate the difficulties in 
achieving the desired sample 
size; an example taken from 
individuals presenting to UHA 
between 01/02/2008 and 
01/02/2009. 
 
 
 
Substantially more patients were identified and recruited from UHA than from the other 
hospitals (Table 4).  I obtained an honorary contract at UHA and personally searched 
the patient database of all stroke admissions.  Thus it is feasible that a more thorough 
search of patient records, including discharge and clinic letters, permitted greater 
identification.  Such a search was not possible at other hospital sites.   
 
 
 
 
 
 
540 Stroke admissions
55 Coded as lacunar 
stroke
25 met selection 
criteria
6 
participated
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Hospital Eligible Participated 
UHA 25 6 
Royal Liverpool University Hospital and 
Broadgreen Hospital 
9 3 
Walton Centre for Neurology and 
Neurosurgery 
5 2 
Royal Preston Hospital 4 0 
Countess of Chester Hospital 9 3 
Total: 52 14 
Table 4: Derivation of included patients. 
 
 
5.2 Participant demographics 
 Controls Patients p-values  
Number 16 11 - 
Mean age (years) ± 
SD 
60.9 ± 6.9 59.5 ± 6.7 0.60 
Female, n (%) 8 (50) 2 (18) 0.086 
Mean education 
(years) ± SD 
16.2 ± 2.6 14.5 ± 3.3  0.16 
Mean BMI (kg/m
2
) 
± SD 
27.5 ± 4.4 28.7 ±6.8 0.61 
Mean pulse  ± SD 71.0 ± 7.65 72.7 ± 10.0 0.63 
Mean systolic BP  
± SD 
130.6 ± 15.4 136.2 ± 19.5 0.44 
Mean diastolic BP  
± SD 
79.3 ± 11.1 77.5 ± 10.8 0.69 
Table 5: Participant demographics; SD = Standard deviation, BMI = Body Mass Index. 
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There were no significant differences in age, sex, years of education, BMI, pulse or BP 
between patient and control groups (Table 5).  Although not statistically significant (p = 
0.086) there were substantially fewer women in the patient (18%) compared to the 
control (50%) group.  
 
 
5.3 Neuropsychological test results 
Results from two out of the four cognitive tests differed significantly between patient 
and control groups (Table 6).  However, after correction for multiple tests, only the 
DSST score remained significant (p < 0.0125).  The DSST score was thus used as a 
standard surrogate measure of clinical severity against which to compare any 
differences in „n‟ and other possible markers that showed a significant difference 
between control and patient groups.   
 
Cognitive tests Controls Patients p 
Trail making B – A 
(seconds) 
22.7 ± 16.6 32.3 ± 19.9 0.21 
Digit span 
backward 
7.7 ± 1.9 6.4 ± 3.2 0.24 
Digit symbol 
substitution test 
56.8 ± 10.0 38.1 ± 9.3 0.000052 
Verbal fluency 
FAS total 
54.9 ± 14.7 41.4 ± 16.3 0.040 
Table 6: Mean cognitive scores ± standard deviation for patients and controls.  
Significant differences (p < 0.05) in test results are highlighted. 
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5.4 Stroop Task 
Patients were significantly slower (p = 0.049) than the controls at the Stroop Task 
(Figure 16).  There was no significant difference in accuracy. 
   
Figure 16: Bar charts with standard error bars to demonstrate the difference in 
accuracy (left) and response time (right) to the Stroop Task between controls and 
patients. 
 
5.5 Neurovascular coupling parameter ‘n’ 
BOLD activation was extremely robust and covered the whole brain at p = 0.05 
corrected for false discovery rate (193,194).  Therefore, ROI were restricted by cluster 
size rather than by statistical threshold.  Each ROI was limited to a cluster size of 1000 
voxels.  Eleven activated ROI were identified (Figure 17).  The Talairach daemon (195) 
was used to confirm the central Talairach coordinates (x, y, z) and anatomical label for 
each region: 
 Left medial frontal gyrus (LMeFG; -9, -1, 48) 
 Right medial frontal gyrus (RMeFG; 6, 8, 43) 
 Left middle frontal gyrus (LMiFG; -40, 34, 24) 
 Right middle frontal gyrus (RMiFG; 37, 25, 33) 
 Left insula (LI; -32, 17, 14) 
 Right insula (RI; 33, 18, 10) 
 Left precentral gyrus (LPCG; -35, -23, 54).  This is the primary motor area. 
 Right precentral gyrus (RPCG; 43, -1, 36) 
 Left parietal lobe (LPL; -30, -63, 42) 
 Right parietal lobe (RPL; 26, -64, 41) 
 Left inferior parietal lobule (LIPL; -38, -50, 39) 
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Figure 17: ROI 
selected for 
analysis are 
circled. 
I PCG MiFG 
MeFG LIPL PL 
The results were averaged over the following larger regions for analysis: frontal 
(incorporating LMeFG, RMeFG, LMiFG, RMiFG and RPCG), parietal (LPL, RPL and 
LIPL), insular (LI and RI), motor (LPCG) and overall (all ROI) regions.  
 
 
 
 
 
 
 
 
 
 
Negative values of „n‟, „M‟ or „CMRO2‟ were excluded from the raw data, as these 
were deemed to be physiologically implausible.  Negative values were attributed to 
noise in the data, or experimental error, for example a poor connection leading to 
incorrect end-tidal oxygen values.  Outliers, defined as values more than three standard 
deviations greater than the mean, were also discarded.  There were no values of „n‟, „M‟ 
or „CMRO2‟ for the patient in whom there was no oxygen calibration scan.  In total 9% 
of the raw data were excluded.  Of the excluded data 72.7% were due to negative 
values, 22.7% due to SVD1 (patient without oxygen calibration scan) and 4.5% due to 
outliers. 
 
The neurovascular coupling parameter „n‟ was reduced in the patient group compared to 
the control group (p = 0.021) (Figure 18). 
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Figure 18: Bar chart with standard error bars showing a reduction in ‘n’ in patients 
with cSVD compared with controls.  
 
 
Figure 19: Bar chart to show differences in 'n' between patient and control groups 
across regions, with standard error bars. 
  
„n‟ appears to be consistently reduced in patients in all individual regions, but with no 
clear regional variation graphically (Figure 19).  A one way ANOVA with repeated 
measures and Greenhouse-Geisser correction showed no significant difference between 
regions of interest (Box 5).   
0
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 (I) ROI (J) ROI 
Mean 
Difference (I-J) Std. Error Sig.
a
 
95% Confidence Interval for 
Difference
a
 
Lower Bound Upper Bound 
Frontal Parietal -.162 .199 1.000 -.757 .432 
Insular -.422 .243 .603 -1.146 .303 
Motor -1.041 .527 .386 -2.613 .530 
Parietal Frontal .162 .199 1.000 -.432 .757 
Insular -.259 .298 1.000 -1.150 .631 
Motor -.879 .504 .597 -2.384 .626 
Insular Frontal .422 .243 .603 -.303 1.146 
Parietal .259 .298 1.000 -.631 1.150 
Motor -.620 .448 1.000 -1.956 .716 
Motor Frontal 1.041 .527 .386 -.530 2.613 
Parietal .879 .504 .597 -.626 2.384 
Insular .620 .448 1.000 -.716 1.956 
Box 5: One-way ANOVA with repeated measures comparing n in ROI. Adjustment for 
multiple comparisons: Bonferroni. 
 
„n‟ was compared to DSST separately for patient and control groups (Figure 20).  The 
patient group showed no association between DSST and „n‟ (p = 0.74, r2 = 0.014).  The 
control group showed no association between DSST and „n‟ (p = 0.16, r2 = 0.14).  The 
relationship between DSST and „n‟ was reassessed with a possible outlier removed 
apparent for the purposes of discussion (Figure 21). 
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Figure 20: Comparison of DSST and ‘n’ in patient and control groups. 
 
 
Figure 21: Graph showing a correlation between DSST and ‘n’ in the control group, 
once an apparently anomalous result had been removed. 
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5.6 Additional functional measures 
5.6.1 BOLD 
 
 
The average BOLD signal was not significantly reduced over all regions in the patient 
group compared to the control group (Figure 22).  The BOLD curves were similar for 
both patients and controls, except in the motor region where the amplitude of the BOLD 
signal was reduced in patients compared to controls (Figures 23 and 24). 
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Figure 22: Bar chart to show the 
difference in BOLD signal change 
between patient and control 
groups across selected regions, 
with standard error bars. 
Figure 23: Averaged BOLD 
curves during the Stroop task 
across total (top) and frontal 
(bottom) regions, with standard 
error bars. 
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Motor BOLD curves
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Figure 24: Averaged BOLD curves during the 
Stroop task across (from top to bottom) motor, 
parietal and insular regions. 
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5.6.2 CMRO2 
CMRO2 was not significantly different between the patient and control groups (Figure 
25). 
 
 
5.6.3 CBF 
Resting CBF was not significantly different between the patient and control groups 
(Figure 26). 
 
 
 
 
 
 
 
 
 
 
Figure 25: Bar chart to 
show the difference in 
CMRO2 between patient 
and control groups across 
selected regions, with 
standard error bars. 
Figure 26: Bar chart with 
standard error bars to show 
differences in CBF in response 
to the Stroop Task between 
patient and control groups 
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5.6.4 CBF in response to Stroop Task 
There were no significant differences in CBF response to the Stroop Task between 
patient and control groups (Figure 27). 
 
 
 
CBF was not significantly different between the patient and control groups.  There was 
no correlation between „n‟ and CBF in either patient (p = 0.51, r2 = 0.055; Figure 28) or 
control (p = 0.50, r
2
 = 0.033; Figure 29) groups. 
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Figure 27: Bar chart with 
standard error bars to show 
differences in CBF in 
response to the Stroop Task 
between patient and control 
groups. 
Figure 28: Graph showing no significant correlation between CBF and 
‘n’ in the patient group. 
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Figure 29: Graph showing no significant correlation between CBF and ‘n’ in the 
control group. 
 
5.6.5 ‘M’ 
The averaged value of „M‟ was significantly increased in patients in all regions (p = 
0.05) (Figure 30). 
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Figure 30: Bar chart with standard error bars to show 
the differences in M between control and patient groups. 
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A one way ANOVA with repeated measures and Greenhouse-Geisser correction 
showed „M‟ to be significantly increased in frontal regions compared with motor 
regions (p = 0.012) (Box 6).  However, there was no significant difference between M 
in frontal regions compared with parietal and insular regions. 
 
(I) ROI (J) ROI 
Mean 
Difference (I-J) Std. Error Sig.
a
 
95% Confidence Interval for 
Difference
a
 
Lower Bound Upper Bound 
Frontal Parietal .596 .458 1.000 -.760 1.953 
Insular .651 .411 .785 -.568 1.870 
Motor 1.544
*
 .428 .012 .276 2.812 
Parietal Frontal -.596 .458 1.000 -1.953 .760 
Insular .055 .505 1.000 -1.442 1.551 
Motor .947 .370 .117 -.148 2.043 
Insular Frontal -.651 .411 .785 -1.870 .568 
Parietal -.055 .505 1.000 -1.551 1.442 
Motor .893 .425 .300 -.367 2.152 
Motor Frontal -1.544
*
 .428 .012 -2.812 -.276 
Parietal -.947 .370 .117 -2.043 .148 
Insular -.893 .425 .300 -2.152 .367 
Box 6: One-way ANOVA with repeated measures comparing M in ROI. Adjustment for 
multiple comparisons: Bonferroni. 
 
 
 
Figure 31: Bar chart with 
standard error bars to show 
regional variation in M. 
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Figure 32 demonstrates an inverse correlation between n and M (r
2
 = 0.21, p = 0.017). 
 
 
Figure 32: Scatter graph to show the correlation between ‘M’ and ‘n’. 
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5.7 Structural measures  
5.7.1 Cerebral volumes 
Mean of measured 
volumes as a percentage 
of whole brain volume  
Control Patient p 
Subcortical matter 52.1 ± 3.0 50.5 ± 4.0 0.28 
Grey matter 46.8 ± 3.2 47.3 ± 4.7 0.73 
Ventricular 1.1 ± 0.8 2.2 ± 1.5 0.058 
Table 7: Mean normalised volumes (%) ± standard deviation. 
 
None of the volume measurements were significantly different between patient and 
control groups (Table 7 and Figure 33).  Although the patients‟ ventricles were double 
the size of the controls‟ ventricles, the difference did not reach significance (p = 0.058).   
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Figure 33: Bar charts with standard error 
bars demonstrating the differences in 
normalised brain structure volumes 
between patient and control groups. 
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The volume scores of individual participants were charted against their score on the 
DSST.  The cognitive test score showed a trend towards correlation with all three 
measures, ventricular enlargement (r
2
 = 0.051, p = 0.03) and subcortical atrophy (r
2
 = 
0.19, p = 0.02), but not grey matter atrophy (r
2
 = 0.11, p = 0.09) (Figure 34), but was not 
significant after Bonferroni correction. 
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Figure 34: Scatter graphs to 
show individual normalized 
volume measurements plotted 
against DSST score.  From top 
to bottom: grey matter, 
subcortical matter and 
ventricular volumes. 
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3.7.2 WML 
WML score was greater in patients than controls (p = 0.012) (Table 8).  Frontal (p = 
0.037) and basal ganglia (p = 0.041) regions were particularly affected by WML in the 
patient group.  WML lesion scores for frontal, basal ganglia and total regions were 
individually plotted against DSST score.  There was no correlation between „n‟ and 
WML score in any region. 
 
 
WML Controls Patients P value 
Frontal 13 29 0.037 
Parieto-occipital 9 21 0.082 
Temporal 2 5 0.23 
Infratentorial 0 3 0.19 
Basal ganglia 7 16 0.041 
Total 31 74 0.012 
Table 8: Sum WML by region for patient and control groups.  There were no 
statistically significant values after Bonferroni correction. 
 
3.7.3 Microbleeds 
 
Microbleeds Controls Patients P value 
Infratentorial 2 1 0.85 
Deep 4 2 0.80 
Lobar 4 4 0.50 
Total 10 7 0.80 
Table 9: Total number of microbleeds by region for patient and control groups. 
There was no microbleed result for one patient because the images were unreadable due 
to movement artefact.  There were no significant differences in the number of 
microbleeds between patient and control groups (Table 9). 
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Chapter six: Discussion 
 
6.1 Discussion of findings  
This study used a modified Stroop Task with hyperoxia-calibrated fMRI to investigate 
whether patients with cSVD exhibited differences in NVC when compared to an age-, 
sex- and education-matched healthy control group.  „n‟, a measure of NVC, was 
significantly reduced in the patient group.  „M‟, which represents the theoretical 
maximum BOLD signal change, was significantly increased in patients compared to 
controls.  Furthermore „M‟ was raised in frontal regions compared to motor regions.  Of 
the structural measures, only WML score was found to be more common in the patient 
group compared to control group.  WML score did not correlate with „n‟. 
 
Although neither group showed a significant correlation between „n‟ and DSST, the 
graphical demonstration of the data suggests a trend in the control group.  There is one 
clear anomaly (circled in Figure 20).  If the circled anomaly were to be momentarily 
removed from analysis then there is a clearly significant correlation between DSST and 
„n‟ in the control group (p = 0.0057, r2 = 0.46) (Figure 21).  The study has shown no 
true correlation, but it seems plausible that the study might be under-powered to show 
such a difference.   
 
The haemodynamic response correlates well with neuronal activity in healthy 
individuals, but the correlation is less clear in certain disease states, i.e. there is an 
uncoupling of the neurovascular response (56).  Differences in BOLD signal between 
groups can only be assumed to relate to neural activity if NVC is the same in both 
groups (104).  The findings of the current study show a difference in NVC between 
patients with cSVD and healthy controls.  The results suggest an un-coupling of the 
haemodynamic response to neural demand in patients with cSVD.    
 
In theory, „n‟ suggests itself as a suitable marker for cSVD.  It is a measure of the 
coupling of a vascular response with neural activity.  cSVD affects the small vessels 
that are in close proximity to neural tissue.  The neurovascular unit (NVU) consists of 
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neurones, glia and vascular cells, which are developmentally, structurally and 
functionally closely related (56).  Mediators of NVC are thought to possibly be released 
by cerebral endothelial cells (56).  One might hypothesise that cSVD leads to damage of 
small cerebral vessels which make up the vascular contribution of the NVU, perhaps as 
a result of impaired VMR.  This might prevent the supply of oxygen and glucose and 
the removal of waste products from the neuronal tissue leading to damage of the 
neuronal tissue and eventually to cognitive decline.  If this were the case, that neural 
activity resulted in an imperfect vascular response, or impaired NVC, then „n‟ would be 
a very early marker of cSVD, should it prove to be a sensitive measure of NVC.  The 
current study has shown „n‟ to be reduced in patients with cSVD.  It does not follow that 
„n‟ is an early and sensitive marker of cSVD, nor even of NVC, but it does suggest the 
possibility that it might be. 
 
Impairment of NVC in patients with cerebrovascular disease has been reported in other 
small studies.  Schroeter et al. (49) reported a delay of the haemodynamic response in 
patients with CMA and also an early deoxygenation that was not seen in the control 
group.  These findings were attributed to impaired NVC.  CMA is a term often used 
interchangeably with cSVD.  However, five of the twelve patients with CMA in the 
study by Schroeter et al. (49) had evidence of macroangiopathy. 
 
Rossini et al. (76) also suggest that BOLD fMRI might not accurately define the sites 
and amount of neural activation in response to a task in patients with cerebrovascular 
disease.  In a study of ten patients with a history of stroke or transient ischaemic attack, 
BOLD fMRI activation and neurophysiological events, quantified by 
magnetoencephalography (MEG), were frequently not correlated.  In other words, NVC 
was impaired.  Moreover, impaired NVC correlated with impaired cerebral VMR.   
   
Rossini et al. (76) propose that maximal dilatation of the vascular tree might limit the 
haemodynamic response despite normal neural activity and the normal release of factors 
implicated in initiating the haemodynamic response, such as NO (56).  In other words, 
impaired VMR is not just correlated with, but in fact results in, impaired NVC.   
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Impaired VMR has been shown in patients with cSVD using PET (196), transcranial 
Doppler sonography (26), fNIRS (26,197) and fMRI (198,199).  Terborg et al. (26) 
suggest that impaired VMR in cSVD might explain the pathophysiology of WML: 
episodes of hypotension might result in periods of „critical hypoperfusion‟ in the deep 
white matter due to a failure of autoregulation because of impaired VMR, leading to 
ischaemia.   
 
Impaired VMR has been shown to correlate with impaired NVC (76), and has been 
suggested as a causative factor in WML (26).  One might thus consider a correlation 
between impaired NVC and WML.  However, the current study found no association 
between WML score and „n‟.  
  
Krainik et al. (199) suggest damage to neuronal tissue innervating the vasculature in 
regions adjacent to an infarct as an alternative to impaired VMR as a cause of impaired 
NVC.  A third hypothesis of altered NVC is that release of NO might be limited by 
chronic hypertension (132).  
 
Differences in NVC between diseased and non-diseased groups imply that the BOLD 
signal itself is not a reliable marker of neural activity in diseased groups.  The findings 
of this study lend credence to such a supposition.  There were no significant differences 
in BOLD signal change between patient and control groups.  Reductions in BOLD 
signal have been reported in the literature in patients with stroke (199) and cSVD 
(132,198). Reductions in the haemodynamic response have also been noted in the 
healthy elderly compared to younger persons using fMRI (200) and fNIRS (102).  
However, reduced haemodynamic response might reflect impaired NVC, rather than a 
reduced neural response to functional activation.   
 
The BOLD curves of the patient group in the current study took slightly longer to return 
to pre-stimulus levels in all regions.  This might reflect the longer response time to the 
Stroop Task observed in the patient group.  The prolonged response time in patients to 
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the Stroop Task is in concordance with previous studies of elderly versus young healthy 
individuals (102) and cSVD (49). 
 
A reduction in CBF has been commonly observed in cSVD (55,113,131,167,201-
204,204-206) and has been shown to correlate with cognitive decline (113,205).  The 
results of the current study did not corroborate these findings, however.  CBF in 
response to the Stroop Task was not significantly different between control and patient 
groups.  Resting CBF was also not significantly different.  However, the current study 
showed a tendency to a rise in CBF. Many studies compared a dementia group to a non-
dementia group (55,131,201,203,206).  It might be argued that cerebral atrophy leads to 
dementia and a reduction in CBF, i.e. that observable reductions in CBF are only 
apparent with dementia.  Demented patients were excluded from the current study, 
perhaps explaining why CBF reductions were not observed.  However, the 
comparatively large study of 57 well-selected patients with cSVD by Sabri et al. (113) 
provides strong evidence against such an argument.  They found reduced CBF in 
patients with cSVD in the absence of atrophy and also found CBF to correlate with 
measures of executive function.  However, the reductions in CBF might have been 
related to hypertension rather than cSVD per se.  Of the 57 patients with cSVD 91% 
had chronic hypertension.  There were 19 age-matched controls, but the number of 
hypertensive subjects was not reported nor accounted for.  The significance of no 
difference in resting CBF between groups in the current study is not clear.  This might 
represent a chance anomaly or reflect the small sample size.   
 
The methodology assumes a fixed 5% reduction in CBF during the periods of hyperoxia 
(186).  This assumption is based on the figure used by Chiarelli et al. (170) and 
Goodwin et al. (186).  However, the reduction in CBF during hyperoxia reported in the 
literature is variable, ranging from 5% to 26.8% (170,186,207-209).  Goodwin et al. 
(186) suggest that the reduction in CBF is less with short periods of hyperoxia, though 
the original evidence for this statement is unclear.   
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There is evidence that CBF reduction during hyperoxia changes with age (209).  In 
many respects, cSVD appears to exaggerate age-related changes (7,49).  It is thus 
plausible that the change in CBF during hyperoxia might be different in patients with 
cSVD compared to healthy age-matched controls.  Watson et al. (209) found a smaller 
reduction in CBF in response to hyperoxia in older age groups.  Hypertension is more 
common in older age groups.  One might conjecture that should this finding be 
extrapolated to cSVD, patients with cSVD might have a smaller drop in CBF during 
hyperoxia than age-matched controls.  Thus, if resting CBF is measured during 
hyperoxia, as in the current study, then resting CBF values might appear higher in 
patients with cSVD than in the control group, not due to actual resting CBF but to the 
effect of hyperoxia.  This might account for the (non-significant) finding of a tendency 
towards elevated CBF in frontal regions in the patient group compared to the control 
group, reported in the current study and at odds with the prevailing literature.  
Investigation into the change in resting CBF with hyperoxia in cSVD compared to age-
matched controls is necessary to confirm such a supposition. 
 
Although „n‟ was surprisingly not found to be correlated with CBF in the current study, 
the differences in CBF might have accounted for some of the observed difference in „n‟.  
The results of the current study must be viewed with caution until the effect of 
hyperoxia on CBF in patients with cSVD is elucidated by further research. 
  
Mark et al. (210) have identified a further possible limitation with the oxygen 
calibration technique designed by Chiarelli et al. (170), and used in this study.  
Hyperoxia was fixed rather than altered in response to end-tidal CO2.  Thus, the 
reduction in CBF ought not to be assumed to be constant.  This might introduce bias in 
to the calculation of „M‟. 
 
„M‟ was found to be increased in patients compared to controls.  „M‟ is a local 
parameter used to calculate CMRO2, simplistically described as the theoretical 
maximum BOLD signal change (159).  It is related to baseline CBV and OEF (159): a 
reduction in OEF or CBV correlates with a reduction in „M‟.  This study found„M‟ to be 
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inversely correlated with „n‟ (p = 0.017; Figure 32).  Low values of „n‟ were associated 
with higher values of „M‟.  A similar study by Tak et al. (211) supports these findings:  
in a study of six patients with subcortical vascular dementia compared with six controls, 
using both fMRI (not calibrated) and NIRS, BOLD, CBF and CMRO2 were all found to 
be reduced whilst OEF was increased.   
 
The study by Tak et al. (211) had fewer patients than the current study and took cortical 
metabolic measurements in a disease group with predominantly subcortical disease.  
The fMRI was based on a motor rather than executive task.  Furthermore, one patient 
had CT rather than fMRI.   Despite these limitations, the results of the two studies are in 
concordance with one another.  Tak et al. (211) postulate that in patients with cSVD 
there is a rise in OEF to compensate for reductions in CBF secondary to microvascular 
changes: neurovascular un-coupling is associated with a rise in OEF.  Although the 
current study did not find a drop in CBF or CMRO2, it did find an association between a 
reduction in „n‟ and an increase in „M‟. 
 
Ischaemic damage of the white matter associated with cSVD is thought to possibly lead 
to disconnection of the cerebral cortex from subcortical structures (10,105,201,203).  
The subcortical damage might result in reduced CBF and CMRO2 in the cerebral cortex, 
which in turn might lead to cognitive impairment and dementia (203).   Neither CBF nor 
CMRO2 were significantly reduced in the patient group in the current study, however. 
 
The sample size was too small to detect a significant difference in cerebral volumes 
between patient and control groups, but did show a tendency towards a correlation with 
DSST score for both ventricular enlargement and subcortical matter volume.  Cerebral 
atrophy and ventricular enlargement are strongly correlated with cognitive dysfunction 
(96,109,117,121,126,212-215), but are not specific to cSVD (216-218).  Thus, the 
findings in the literature are mirrored by the findings in the current study: normalised 
brain structure volumes were unable to differentiate participants with cSVD from those 
without, but did tend to correlate with a measure of cognitive dysfunction (DSST score).  
A large long term longitudinal study with strict entry criteria would be necessary to 
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determine a temporal relationship between cerebral atrophy and cognition.  Due to its 
cross-sectional nature, the current study cannot provide evidence as to whether atrophy 
leads to cognitive decline or cognitive decline occurs before atrophy.  
 
WML score was significantly higher in the patient group in frontal, basal ganglia and 
total regions and was shown to correlate with DSST score in frontal and total regions.  
The evidence in the literature for the correlation between WML load and cognitive 
dysfunction is mixed as observed in the systematic review (chapter 2).  The result of the 
current study might be interpreted as a direct link between WML and cognitive 
dysfunction.  However, the evidence also fits the „threshold hypothesis‟ (116), which 
states that WML only affect cognition when they are sufficiently severe.  If the two 
most severe WML scores were to be removed from the analysis of the current study of 
total WML score, the correlation between total WML score and DSST score disappears 
(r
2
 = 0.055, p = 0.26).   
 
WML score and „n‟ were both significantly different between patient and control 
groups.  Regression analyses were employed to test for a relationship between WML 
score and „n‟.  No correlation was observed, which might suggest that WML are not 
directly linked to altered NVC.   
  
 
6.2 Strengths of the study 
This study had four particular positive features.  The main strength of this study of 
cSVD was the application of strict entry criteria. A homogeneous group was selected 
that allows the findings to be confidently attributed to cSVD.  Despite the strict criteria, 
it is possible that included patients might have had LACS attributable to an embolic 
source.  However, a recent study of 2875 persons with a first-ever anterior circulation 
stroke showed an athero-embolic cause to be far less likely in LACS than cortical 
strokes (219).  Clinical diagnosis alone is unreliable: 16% of 44 subjects with a clinical 
LACS were found to have a cortical stroke on imaging and 23% of 93 patients with a 
cortical syndrome had an acute lacunar infarct (220).  The combination of a clinical 
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diagnosis of LACS coupled with a radiological diagnosis further reduces the likelihood 
of an embolic cause and is an approach used by leading researchers in the field 
(44,185).  Brain imaging shows evidence of other markers associated with cSVD, 
including EPVS, microbleeds and LA, but have yet been shown to be specific to the 
condition, rather markers of cerebral damage (44). 
 
Secondly, neuropsychological tests were used that were known to be sensitive to the 
changes in executive function associated with the disease.  Thirdly, the patients were 
compared to age- and education-matched controls with similar rates of hypertension.  
Finally, both a novel imaging marker and more traditional structural imaging markers 
were compared in the same groups against the same neuropsychological tests. 
 
 
6.3 Limitations of the study 
There were many limitations of this study, some particular to the methodology and 
some associated with the difficulties in the investigation of cSVD.  The overwhelming 
weakness was the inability to obtain the desired number of patients.  Fourteen were 
recruited, of whom ten provided data for the calculation of „n‟.  Furthermore, just less 
than 10% of the data had to be excluded due to noise.  It was calculated that a minimum 
of 16 patients would be needed to detect a 25% change in „n‟.  It is clear that 
associations with „n‟ might have been missed due to under-powering of the study.  
Considerable effort was made to encourage recruitment.  The study was adopted by the 
SRN which facilitated access to a larger pool of potential patients.  However, the 
primary strength of the study was the predominant cause of the primary weakness.  
Stringent entry criteria, necessary to establish a meaningful study group, greatly limited 
the number of suitable patients.  The study offered no direct benefits to the individual 
patients.  Moreover, it involved a long time in the confined space of the MRI scanner, 
which many individuals would find disquieting. 
 
There were also limitations in the selection of controls.  Patient and control groups were 
not well-matched for gender, although the difference was not statistically significant (p 
90 
 
= 0.086).  That was a result of insufficient patient recruitment.  Fewer females with 
cSVD participated in the study.  There is some evidence to suggest that gender may 
affect the components of the haemodynamic response (221-225), albeit inconclusive.  In 
response to a visual task, BOLD amplitudes have been found to be significantly higher 
(222) and also lower (223) in women compared to men.  
 
Many of the controls were selected from a university population.  They might be better 
educated and thus likely to perform better on cognitive tests.  The number of years of 
education was recorded for each participant and overall did not differ significantly 
between control and patient groups.  However, the National Adult Reading Test 
(NART) might have offered a better measurement of pre-morbid intelligence to account 
for any bias in the cognitive tests arising from differences in pre-morbid intelligence 
(226). 
 
Furthermore, subjects with cortical stroke might have provided a better control group 
for radiologically-confirmed LACS (44).  Cardiovascular risk factors such as 
hypertension and diabetes, as well as, for example, antihypertensive medications would 
be better balanced between the groups. 
 
The measurement of cerebral volumes was not performed blind to the participant‟s 
group (patient or control).  Differences noted in these measures may have been subject 
to an observer bias.  Measures of WML and microbleeds were performed blind.  It is 
possible that the appearance of morphological features associated with cSVD (WML 
lacunes and microbleeds) may have inadvertently influenced measurements.  However, 
those morphological features associated with cSVD have also been noted in the elderly 
and so might be expected in the controls (1,14,32). 
 
Venous oxygen concentration was calculated based upon end-tidal oxygen 
concentration, with an assumption that oxygen exchange across the vessel wall is 
similar in both groups and that the resting state OEF is the same in both groups.  
However, there is evidence that the OEF might in fact be increased in VaD (201,203) 
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and silent brain infarction (227), which might confound the findings.  The significant 
rise in „M‟ suggests that OEF might be increased in patients with cSVD in this study 
and thus be a serious confounding factor, although the findings are supported by Tak et 
al. (211).  A method to directly sample venous oxygen concentration might remove this 
potential bias.   
  
This is the first study to try to investigate „n‟ using oxygen-calibrated fMRI in patients 
with cSVD.  Confounding factors such as CBF response to hyperoxia, as discussed 
above, might introduce error into the results. 
 
Ideally, the study would have been able to directly compare DTI measures to fMRI and 
structural findings in this well-selected cSVD population.  However, inclusion of DTI 
would have increased scan time to an unreasonable length.  
 
The quality of the MRI images was also limited by the time spent in the scanner.  Had 
participants been scanned over two sessions of an hour each, better quality images 
might have been made.  However, this was considered too expensive and time-
consuming for the current study. 
 
fMRI is particularly sensitive to motion, caused by participants moving their head and 
also internal pulsations associated with respiratory and cardiac cycles (161).  The 
interference from motion is limited by keeping the head still with pads and by motion 
correction, which uses automated algorithms to realign brain volumes (161).  Motion 
prevented the reading of a SWI of one patient to determine their microbleed score.  It is 
feasible that motion might have had an effect on the fMRI data. 
 
6.3.1 Limitations of studying cSVD 
The necessity of strict entry criteria is a result of the difficulties associated with 
identifying a group of patients with cSVD.  These inclusion and exclusion criteria allow 
selection of patients with a high likelihood of cSVD, but there is no practical „gold 
standard‟ against which to confirm the diagnosis of cSVD.  Routine post mortem 
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examination is insufficient as it does not include the exacting process of sectioning the 
small penetrating cerebral vessels.  Furthermore, the interval from the onset of lesions to 
the time of autopsy, coupled with the insidious onset of cognitive symptoms creates 
difficulties in associating structural lesions to the clinical picture (8). 
  
Related to the difficulty in diagnosing cSVD is the charting of its progression, which 
can be estimated by clinical measures of severity or morphological changes such as 
WML progression.  However, as previously demonstrated, there is no consistent 
correlation between these two methods of assessing progression, that is clinical and 
observable lesion changes.  This study used neuropsychological test scores as a standard 
against which to assess the severity of cSVD, which have been shown to discriminate 
patients with cSVD from healthy age- and education- matched controls, with a 
sensitivity and specificity both of 88% (9).   
 
A further limitation to the well-selected cSVD study population used is that the findings 
cannot be transferred to other populations, including individuals with evidence of cSVD 
but who have not had a stroke, in whom preventative action might be particularly 
beneficial.  However, the findings of this and similar studies might be used to formulate 
hypotheses in broader populations, such as the general elderly. 
 
Despite the difficulties involved in the study of cSVD, it represents an exciting area of 
research, with the potential to influence clinical care.  A few ideas for further study are 
suggested in Box 7. 
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Box 7: Ideas for further study. 
 
 
 
 
 
 
 Validation of results in studies with a larger sample size. 
 Validate the oxygen-calibration technique in patient groups. 
 Cross-sectional studies, such as the current study, do not elucidate causation.  
More robust conclusions might be made if the patients were followed up over 
several years in a longitudinal study. 
 A longitudinal study with eventual pathological confirmation of cSVD. 
 Direct DTI comparison with „n‟ in a cSVD population. 
 Small vessel disease of the brain might be related to small vessel disease of 
other organs, e.g. the kidneys, and as such might represent a systemic 
disorder (206). 
 Apply the study methodology to assess changes in NVC in different 
populations: 
o VaD 
o Community-dwelling elderly 
o Individuals with evidence of cSVD, but no clinical stroke 
 A large series of RCTs involving patients with cSVD to elicit appropriate 
management, including the benefits of: 
o Aspirin 
o Anti-hypertensives 
o Statins 
o Intravenous magnesium in the acute setting 
o Donepezil 
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Chapter seven: Conclusions 
A reduction in „n‟ was observed in patients with likely-cSVD compared to age-, gender- 
and education-matched controls using hyperoxia calibrated fMRI.  These disparate 
values of „n‟ signify altered NVC in patients with cSVD.  The finding of altered NVC 
indicates that BOLD signal change does not represent a good imaging marker for cSVD 
as it does not accurately reflect neural activity in patients with this disease.  „n‟ was 
inversely correlated with „M‟, which might indirectly suggest that altered NVC is 
associated with a raised OEF and loss of metabolic reserve. This is one of the first 
studies to investigate „n‟ in cSVD and therefore these preliminary results, based upon a 
small sample size, require validation in larger studies.   
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Appendix A:  Summary of studies reviewed in chapter 2 
 
Key: 
* = Significant difference at p<0.05 
N= Number; A= Mean age in years; E= Years of education in years; F= Percentage 
females; HT= Percentage hypertensive; LI= Lacunar infarct (visible on MRI); LACS= 
Lacunar syndrome (clinical diagnosis); LA= Leukoaraiosis (White matter 
hyperintensities on MRI); CeVD= Cerebrovascular disease; VaD= Vascular dementia 
Imaging modalities: CT= Computed Tomography; MRI= Magnetic Resonance 
Imaging; MRS= Magnetic Resonance Spectroscopy; DWI= Diffusion Weighted 
Imaging; DTI= Diffusion Tensor Imaging; PET= Positron Emission Tomography; 
SPECT= Single Photon Emission Computed Tomography; fNIRS= Functional Near-
Infrared Spectroscopy 
NAWM= Normal appearing white matter; FA= Fractional anisotropy; MD= Mean 
diffusivity; NAA/Cr= N-acetylaspartate/ creatine ratio 
Neuropsychological tests: EXEC= Executive (test); MMSE= Mini-Mental State 
Examination; CDR= Clinical Dementia Rating scale; WAIS-R= Wechsler Adult 
Intelligence Scale-Revised; TMT= Trail making Test; WCST= Wisconsin Card Sorting 
Test; DRS= Dementia Rating Scale; MDRS I/P= Mattis Dementia Rating Scale- 
Initiation Perseveration; BADS= Behavioural Assessment of the Dysexecutive 
Syndrome; NART-R= National Adult Reading Test-Restandardised; SSS= 
Scandinavian Stroke Scale 
NINDS= NINDS-AIREN criteria for the diagnosis of vascular dementia 
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Appendix B:  Participant consent form 
January 2008, version 2 
 
CONSENT FORM 
 
Title of Project:  
Cerebral small vessel disease: novel MRI markers and cognitive dysfunction 
 
Name of Researchers:  
Dr H Emsley (University of Liverpool and The Walton Centre) 
Dr L Parkes (University of Liverpool)   
Please initial box 
1. I confirm that I have read and understand the information sheet dated January 
2008 (version 2) for the above study and have had the opportunity to ask 
questions. I agree to comply with the procedures as set out in the information 
sheet. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to my 
taking part in research. I give permission for these individuals to have access to 
my records. 
 
4. I agree that personal data relating to myself (as defined by the Data 
Protection Act, 1998), being used for research purposes only. I 
understand that my personal information will be kept for up to fifteen 
years and then will be confidentially destroyed. 
 
5. I consent to my GP being informed of my participation in this study and that 
they may be contacted for any relevant medical information as required. 
 
6. I agree to be contacted at six monthly intervals over the next two years, to be 
informed of the progress of the study and to discuss any health changes. 
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7.  I agree to take part in the above study.     
  
 
 
 
____________________________  ____________    ____________ 
Name of Participant    Date    Signature 
 
 
 
____________________________  ____________  ____________ 
Name of Person taking consent   Date   
 Signature 
(if different from researcher)   
 
 
____________________________  ____________  ____________ 
Researcher     Date    Signature 
 
1 copy for participant, 1 copy for researcher, 1 copy for hospital notes (if a patient) 
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Appendix C: Heading letter for participants 
       Mr Guy Lumley 
Research Assistant           Mr Guy Lumley 
MARIARC 
Pembroke Place 
Liverpool 
15
th
 July 2009                  L69 3GE 
Dear Mr , 
I write with reference to a trial we are running at the University of Liverpool into 
lacunar strokes and wondered if you would consider volunteering. 
Please find enclosed details on the trial and what your participation would involve, as 
well as directions to the Magnetic Resonance and Image Analysis Research Centre 
(MARIARC).  If you‟ve any questions, please don‟t hesitate to contact me by letter, 
telephone 0151 7954622, or email G.N.Lumley@liv.ac.uk. 
If happy to participate, you would be asked to come into MARIARC for approximately 
3 – 3½ hours.  The session would involve a clinical assessment, including a brief 
examination.  We would test cognitive function (thinking abilities), which includes a 
series of complicated computerised tests.  These assessments usually take 1 hour in 
total.  We would also need you to have a detailed MRI scan, which also last about 1 
hour.   
Prior to scanning you would need to be screened to check that it is safe to scan you.  
This involves filling in a form with a qualified radiographer at MARIARC.  For the 
scan, you would be asked to change into a gown in the changing rooms provided.  If 
you wish, you are welcome to bring a T-shirt and pyjama bottoms to wear under the 
gown, providing they contain no metal.  There are lockers available for your personal 
belongings.   
For part of the scanning procedure you would be asked to wear a mask that allows us to 
deliver oxygen-rich air.  You would also be asked to do another test inside the scanner. 
Yours sincerely,  
Guy Lumley (Research Assistant) 
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Appendix D: Patient information sheet 
January 2008 
Patient Information 
CEREBRAL SMALL VESSEL DISEASE: 
NOVEL MRI MARKERS & COGNITIVE DYSFUNCTION 
 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and 
discuss it with others if you wish. Please ask us if there is anything that is not 
clear or if you would like more information on.   Thank you for reading this. 
 
What is the purpose of the study? 
Stroke is an important cause of damage to the brain leading to death or 
disability. Around one quarter of strokes are due to „small vessel disease‟.  This 
type of stroke has been studied less and we know little about what happens to 
patients in the longer term after having a small vessel stroke, including what 
happens to their cognitive function (or thinking processes). We are also unsure 
about what the best scanning tests are for small vessel strokes. We aim to 
investigate new and revised scanning tests using magnetic resonance imaging 
(MRI) techniques. Gaining information as to whether these different tests can 
be related to any possible problems with thinking processes. The whole study 
will last for at least 2 years. 
 
Why have I been chosen? 
You have been chosen because you have either had a lacunar stroke (a type of 
small vessel stroke) or your brain scan shows some changes like those that we 
see in this type of stroke.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form.  If you decide to take part you are still free to withdraw at any 
time and without giving a reason.  A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive now or 
in the future. 
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 What will happen to me if I take part? 
If you have had a stroke we will ask you about this, we will also obtain details 
from your medical notes.  
  
We will perform a clinical assessment, including brief examination. We will 
also perform an assessment of cognitive function (thinking abilities), including 
a range of computerised tests. These assessments would take approximately 1 
hour in total. We would also need you to have detailed MRI scans, also lasting 
approximately 1 hour.  
 
We would arrange for you to attend the Magnetic Resonance and Image 
Analysis Research Centre (MARIARC) at the University of Liverpool, where 
the clinical assessment, tests of cognitive function and MRI scans will be 
performed. There will be a nurse at MARIARC (but no doctor present) to guide 
you through these tests and scans. We are willing to pay for your transport to 
and from MARIARC, or organise a taxi if this is preferable. The scans at 
MARIARC will be in addition to any other scans that are part of your care. 
 
Prior to scanning you will need to be screened to check that you are safe to be 
scanned. This involves filling in a form with a qualified radiographer at 
MARIARC. Prior to the scanning procedure, you will be asked to change into a 
gown in the changing rooms provided. If you wish you may bring a t-shirt and 
pyjama bottoms to wear under the gown, providing it contains no metal. There 
will be lockers available for your personal belongings which can be locked 
during the period of the study. 
 
For part of the scanning procedure you will be asked to wear a mask that will 
allow us to deliver oxygen-rich air. You will also be asked to perform a number 
of tasks inside the scanner, such as making judgments about words presented on 
a screen.  
 
We would like to contact you again in the future, at 6 monthly intervals by 
telephone or in writing, and after two years so that we can arrange to see you 
again to repeat the clinical assessment, tests of cognitive function and MRI 
scanning so that we can compare these tests with the first tests you had.  
 
What do I have to do? 
Participation in this study does not require any additional visits to the hospital, 
and only requires you to attend MARIARC for the clinical assessment, tests of 
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cognitive function and MRI scans. No special preparations or changes in 
medication or lifestyle are needed.  
 
What are the possible disadvantages and risks of taking part? 
There are no particular disadvantages or risks because MRI is generally safe. 
The scanner experience is noisy, and has been reported as „claustrophobic‟, 
causing some anxiety in a small number of individuals. If you experience any 
distress, the scanning process will be immediately discontinued.  
The MRI scans will be looked at and reported by a consultant neuroradiologist. 
If the neuroradiologist notices something abnormal (in addition to the effects of 
any small vessel disease) and if this is considered to be clinically important then 
a report will be sent to your General Practitioner (GP). The images collected for 
this study are not a typical clinical MRI series and would not however be made 
available for diagnostic purposes. 
 
What are the possible benefits of taking part? 
There are no direct benefits to you personally from participation in the study. 
However we hope that the information we gain from the study will help us to 
identify what the best scans are to obtain improved MRI markers of small vessel 
stroke, and whether these may relate to possible problems with cognitive 
function (thinking processes).  
 
What if new information becomes available? 
Sometimes during the course of a research project, relevant information 
becomes available.  If this happens, a member of the research team will tell you 
about it. Also, on receiving new information the research team might consider it 
to be in your best interests to pass this information to your own doctor, or even 
withdraw you from the study.  The research team will explain the reasons and 
arrange for your care to continue.  
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone‟s negligence, 
then you may have grounds for a legal action but you may have to pay for it.  
Regardless of this, if you wish to complain about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
complaints mechanisms should be available to you. 
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Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of this research 
will be kept strictly confidential in line with the data Protection Act 1998.  Any 
information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised from it. Your GP will be 
informed of your participation in this study. The results of your tests will be 
made available to other doctors in this hospital or other hospitals who may be 
directly involved in your future medical care. 
 
What will happen to the results of the research study? 
After analysis of the results of all the participants in the study, we aim to 
publish the conclusions in a peer-reviewed medical journal. Your individual 
results will not be identifiable in any report or publication. You will however be 
able to obtain a copy of any published report by contacting us in the future. 
 
Who is organising and funding the research? 
The research is organised by Dr Emsley (University of Liverpool and The 
Walton Centre) and Dr Parkes (University of Liverpool). None of the research 
team receives any direct payment for this research. The research is being funded 
through financial support from Unilever. It is possible that additional or 
alternative sources of funding will be identified during the course of the 
research. 
 
Who has reviewed the study? 
The Local Research Ethics Committee has reviewed this study. 
 
Contact for further information 
We suggest you contact Dr Parkes if you require further information. She is 
contactable on 0161 2755577. Thank you for taking part in this study. 
 
You will be given a copy of this Participant Information Sheet and a signed 
consent form to keep. 
 
Patient Information number for this trial: 
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Appendix E:  Presentations resulting from this work 
 
 
1. Parkes LM, Lumley G, Mohtasib RS, Emsley H, Goodwin JA „Calibrated fMRI 
reveals altered neurovascular coupling with age during a cognitive Stroop task‟ 
ISMRM Honolulu [2009]. 
2.  Goodwin JA, Lumley G, Irwin A, Emsley H, Parkes LM „Hyperoxia calibrated 
fMRI of cerebral small vessel disease during a cognitive Stroop task‟ ISMRM 
Honolulu [2009]. 
3. Lumley G, Goodwin J, Parkes LM, Emsley HCA. Executive and frontal 
dysfunction in an fMRI study of cerebral small vessel disease; ABN 
(Association of British Neurologists) conference Liverpool [2009].  To be 
published in abstract form in JNNP (Journal of Neurology, Neurosurgery and 
Psychiatry). [Oral presentation by the first author]. 
4. Lumley G, Goodwin J, Parkes LM, Emsley HCA. Executive and frontal 
dysfunction in an fMRI study of cerebral small vessel disease; North England 
Neurological Association annual conference Harrogate [2009].  [Oral 
presentation by the first author]. 
5. Lumley G, Goodwin J, Parkes LM, Emsley HCA. Executive and frontal 
dysfunction in an fMRI study of cerebral small vessel disease; UK Stroke Forum 
conference Glasgow [2009].  [Oral presentation by the first author]. 
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Glossary 
ASL  Arterial spin labelling 
BBB  Blood-brain barrier 
BOLD  Blood-oxygen-level-dependent 
BP  Blood pressure 
CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy 
CBF   Cerebral blood flow 
CBV  Cerebral blood volume 
Cho  Choline 
CDR  Clinical Dementia Rating 
CHS  Cardiovascular health study 
CMA  Cerebral microangiopathy 
CMRO2 Metabolic rate of oxygen  
COPD  Chronic obstructive pulmonary disease 
Cr  Creatine 
CSF  Cerebrospinal fluid 
cSVD  Cerebral small vessel disease 
CT  Computed tomography  
DSST  Digit symbol substitution test 
DTI  Diffusion tensor imaging 
DWI   Diffusion-weighted imaging 
EEG   Electroencephalography 
EPVS  Enlarged perivascular space 
FLAIR  Fluid attenuated inversion recovery 
fMRI   Functional magnetic resonance imaging 
(f)NIRS  (Functional) near-infrared spectroscopy 
FWHM  Full width at half maximum 
GABA  Gamma-aminobutyric acid 
GLM   General linear model 
HDL   High-density lipoprotein 
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LA   Leukoaraiosis 
LDL   Low-density lipoprotein 
LI   Lacunar infarct 
LILACS  Liverpool lacunar stroke study 
LIPL   Left inferior parietal lobule 
(L/R)MeFG  (Left/ right) medial frontal gyrus 
MARIARC   Magnetic resonance and image analysis research centre 
MDRS-I/P   Mattis dementia rating scale-initiation/ perseveration subscale 
MEG    Magnetoencephalography  
MiFG   Middle frontal gyrus 
MMSE   Mini-mental state examination 
MRA    Magnetic resonance angiography 
MRI   Magnetic resonance imaging 
MRS   Magnetic resonance spectroscopy 
NAA   N-acetylaspartate 
NIHSS  National Institute of Health Stroke Scale 
NO   Nitric oxide 
NVC   Neurovascular coupling 
NVU   Neurovascular unit 
PCG   Precentral gyrus 
PET   Positron emission tomography 
PL   Parietal lobe 
PROGRESS  Perindopril protection against recurrent stroke study  
PROSPER  Pravastatin in elderly individuals at risk of vascular disease (study) 
RCT    Randomised controlled trial 
RF   Radiofrequency 
ROI   Region of interest 
SNR   Signal to noise ratio 
SPECT  Single photon emission computed tomography 
SRN   Stroke Research Network 
SWI   Susceptibility-weighted imaging 
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Syst-Eur  Systolic hypertension in Europe (study) 
TE   Echo time 
TI   Inversion time 
TR   Repetition time 
UHA   University Hospital Aintree 
VaD   Vascular dementia 
VMR   Vasomotor reactivity 
WML   White matter lesion 
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